Clinical trial NCT04170738
Conditions: Attention Deficit Disorder With Hyperactivity Conduct Disorder Substance Abuse
Keywords: ADHD substance abuse risk Adderall fMRI ADHD Treatment Medication
Sponsor: Jeffrey Newcorn
Start date: 2019-11-05; Completion date: 2023-08-08
Enrollment: 33 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
Childhood ADHD and comorbid oppositional defiant disorder (ODD) and conduct disorder (CD) are considered risk factors for subsequent substance abuse, and youth with both ADHD and ODD/CD are at greatest risk.

However, the effects of treatment of ADHD with stimulant medications such as methylphenidate (MPH) and mixed amphetamine salts (MAS) on risk for substance abuse are poorly understood. The study team propose to use fMRI to study the effects of extended release mixed amphetamine salts (MAS-XR) in drug-naïve youth 7-12 years at low risk (i.e., ADHD only) and high risk (i.e., ADHD + ODD/CD) for substance abuse on the brain reward system, to better understand the potential impact of these medications on an aspect of brain functioning which is thought to underlie vulnerability to substance abuse.

Detailed description:

Arms: arm 1: dosage = start at 0.25-0.50mg/kg, adjusted as necessary pills by mouth
Interventions: intervention 1: Adderall
Intervention descriptions: intervention 1: 3 weeks of Adderall

Protocol documents:
Prot_SAP_000.pdf: 
Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for 
Substance Use Disorder
PI: Jeffrey Newcorn
NCT04170738
Document Date: 12-19-2023


INTRODUCTION TO REVISED APPLICATION
We thank the reviewers for their thoughtful feedback and positive comments about the significance of the 
project, the team’s qualifications and our research environment. They also had some concerns, which we have 
addressed in the revised proposal and below.
Significance:
Rev. 3 (R3): “premise for the … between-group difference in reward-induced activation of insular and ventral 
striatum is not sufficiently elaborated.” Refs 16 & 17 do not support hypothesis of changes in ventral striatum.
Response: We have revised hypotheses regarding the insula but not the ventral striatum based on new 
preliminary data showing between-group activation differences in insula, putamen and ACC (not ventral 
striatum) in high-risk (HR) vs. low-risk (LR) and control groups (see section C.3.3. Preliminary Studies). 
R3: “The need for the formulation of two mutually exclusive hypotheses (HR>LR and LR>HR) is not clear.” 
Response: We have clarified our aims and hypotheses to focus on single hypotheses: 1) group differences 
in baseline activation (We hypothesize HR>LR based on new preliminary data), and 2) group differences in 
effect of MAS-XR (We hypothesize greater reduction in activation for the HR vs. LR groups). 
Investigator(s):
R2: Since Dr. Fan is not listed under key personal, “concern that expertise with ACR is lacking.” “Is there a 
member of the team qualified to administer the ACR task?”
Response: Dr Fan is added as key personnel. Dr Ivanov also has extensive experience administering ACR 
in children and will train a research associate to run ACR training of study participants.
Approach:
R1, R3: concern regarding whether 3 week post-treatment is sufficient to show changes in reward response. 
Rationale for 3 week period is based on pre-clinical study.” 
Response: There are no published data regarding treatment effects on activation of the brain reward 
system. We will test for changes following 3 weeks of stimulant treatment, which has produced changes in 
activation in adults with ADHD (Yang et al., 2016, ref 66 in the proposal). 
R1: concern re: possible confounding effects of family history of SUD (allowed in the high risk but not low risk 
group. 
Response: Ideally we might add a positive family history-only group, but this would exceed the scope of a 
pilot/feasibility study. We will therefore exclude SUD family history for the LR and HR groups.
R1: Much of the inclusion and exclusion criteria and recruitment/retention strategies were in Human Subjects.
Response: This is now included in the main document.
R1: Unequal number of males and females will be recruited, no analysis of sex effects.
Response: Sex will be included as a covariate.
R1: Practice effects are not discussed.
Response: Prelim. data (4 subjects scanned 2X with no intervening intervention) show no practice effects.
R2: Preferable to pre-specify the washout period for all subjects on non-stimulant treatments.
Response: A 2-week washout period is now specified. 
R2: Inconsistency regarding family history of SUD in 1st degree relatives (pg 53 vs. C.2.2).
Response: We clarified that FH is excluded in both the HR and LR groups.
R2: Reference is made to pilot data, but a small section on Preliminary Studies is included with no data.
Response: We now include a graph summarizing our preliminary data.
R3: The power analysis is not sufficiently elaborated.
Response: We revised the power analyses section.
R3: The section “Dose titration” indicates that some patients may receive different doses of MAS-XR. No 
statistical control for dose variation is proposed. 
Response: A variable for dose is now added into the analyses.
R3: outcome changes might be a result of the acute and/or extended effects of treatment. Time from the last 
medication dose and the scan is not provided.
Response: There will be a 6-8h interval between drug administration and scanning (now specified). Thus, 
activation changes detected on 2nd scan will reflect changes during treatment rather than acute drug effects.  
R3: minor: a number of mistakes/typos.
 Response: They have been corrected. 
Contact PD/PI: Newcorn, Jeffrey H
Introduction to Application
Page 55
Effective Date: 12/19/2023
End Date:12/18/2024


Among youth with vulnerability for the development of substance use disorders (SUD), those with attention-
deficit/hyperactivity disorder (ADHD) and conduct disorder (CD) or severe oppositional defiant disorder (ODD) 
are considered to be at highest risk1. Stimulants such as methylphenidate (MPH) and mixed amphetamine 
salts (MAS), and a variety of non-stimulants, have established efficacy for ADHD - but response is greater for 
stimulants than non-stimulants2. Basic science studies have shown sensitizing effects of MPH on the brain 
reward system3 in animal models of SUD risk4,5, with MPH-exposed animals having greater self-administration 
of cocaine6 – which is a cause for concern. However, a recent large meta-analysis found that stimulants can be 
used in youth with ADHD without increasing SUD later in life7; other studies point to benefits of stimulants in 
treating CD8. Yet, no studies have specifically examined stimulant safety in the context of SUD risk status in 
humans. Thus, a question of major clinical import remains: can stimulants can be used safely in youth with 
ADHD and high risk for SUD, or should they be withheld due concerns about increased risk for later SUD?  
Functional magnetic resonance imaging (fMRI) offers an opportunity to examine the effects of stimulant 
medications on the biology of SUD risk in youth with ADHD prior to exposure to drugs of abuse9. Emerging 
findings implicate behavioral disinhibition, heightened sensitivity to reward10, and decreased connectivity 
between the behavioral control and reward systems11-13 in mediating SUD risk. In particular, reduced activation 
in the reward system in preparation of effort, but increased activation following reward receipt, have been 
linked to problematic drug use14,15 - suggesting that SUD risk is characterized by blunted motivation and 
cognitive effort, but enhanced hedonic properties of rewards. Of note, recent findings indicate that purported 
neurobiological manifestations of SUD risk may precede the appearance of clinical manifestations9. Yet there 
are only a few studies reporting on activation changes after administration of stimulants, with discordant 
findings; for instance Rubia et al. (2009)16 showed that MPH decreased baseline hyperactvation in OFC in 
ADHD while Minuzo et al. (2013)17 reported that MPH increased baseline hypoactvation in nucleus accumbens 
(NAcc) for ADHD vs controls. Yet, while subjects in these studies had ADHD, they did not necessarily have 
increased risk for SUD, and the findings were not examined in relation to relative risk for SUD. Importantly, 
preliminary data from our group suggest that youth with ADHD at high risk (HR) and low risk (LR) for SUD 
differ from controls in relation to reward processing, as demonstrated by prediction error outcomes on 
behavioral tasks, as well as activation in the reward system on fMRI. These findings highlight the importance of 
specifically studying the effects of stimulant medication in youth with ADHD and HR for SUD in contrast with 
those at LR for SUD. Currently, there are no studies which use fMRI to examine youth at HR vs. LR before and 
after stimulant treatment. This design would be highly informative for assessing effects of stimulants on the 
biology underlying SUD risk. 
We propose to study the effects of 3 weeks of treatment with mixed amphetamine salts extended release 
(MAS-XR) on the brain reward system in youth with ADHD only (LR) vs. ADHD + CD or severe ODD (HR). We 
will study 36 youth naïve to stimulant treatment and drugs of abuse (18 per risk group) ages 7– 12 years. LR 
and HR subjects will be assessed with clinical and neuropsychological measures and will be subjected to fMRI 
scans twice – before and after 3 weeks of treatment with MAS-XR. The fMRI scans will be conducted while 
participants perform the Anticipation, Reward, Conflict (ACR) task developed by our group, which has a unique 
component of unexpected non-reward18. Combining prediction error analyses with purported activation 
differences on this particular component of the ACR will offer a novel approach to assess differences between 
youth at different risk levels for SUD. Importantly, our event-related design will distinguish increased effort and 
associated anticipatory activation (positive effects) from increased hedonics of reward (a potentially deleterious 
effect).
Aim 1 (Primary). To compare the effect of MAS-XR on activation in the brain reward system in LR vs. HR 
participants with ADHD. Hypotheses: 1a) Based on our preliminary data the HR group will show greater 
baseline activation than the LR group during the ACR task in the insula, putamen, and anterior cingulate gyrus 
(ACC); 1b) Based on prior findings of stimulant effects on baseline hyperactivation in ADHD16, we hypothesize 
that MAS-XR will reduce the activation in the brain reward system for both groups, with greater magnitude of 
change in HR youth. Given discordant reports in the literature16-28, it is possible that MAS-XR will increase the 
baseline activation in both groups or may increase the activation in one group but not the other. 
Aim 2 (Exploratory). We will examine the relationship between behavioral measures and changes in activation 
in the reward system. We hypothesize that changes on behavioral measures will correlate with changes in 
brain activation during the Expected Reward and Unexpected Non-Reward components of the ACR task. We 
will specifically examine: a) positive and negative prediction error measures computed from the behavioral data 
from the ACR task; b) measures of sensitivity to reward and punishment assessed by the subscales from the 
BIS/BAS; and c) positive and negative urgency assessed by the UPPS Behavioral Impulsivity Scale. 
Contact PD/PI: Newcorn, Jeffrey H
Specific Aims
Page 56
Effective Date: 12/19/2023
End Date:12/18/2024


A. BACKGROUND AND RATIONALE.  Vulnerability to substance use disorder (SUD) has been
conceptualized as an imbalance between the functions of the brain reward and behavioral inhibition systems29.
Drug-seeking behavior is linked to the highly rewarding properties of addictive substances, which produce a
preference to drugs over alternative naturally occurring rewards, so drug-associated stimuli acquire heightened
ability to motivate behaviors. An important recent review concludes that adolescents with attention-deficit/
hyperactivity disorder (ADHD) and disruptive behavior disorders (i.e., oppositional defiant disorder (ODD) or
conduct disorder (CD)) exhibit exaggerated sensitivity to rewards in the context of a persistent pattern of
behavioral disinhibition10, and therefore are at heightened risk for SUD. Stimulant medications - the accepted
first-line treatment for ADHD - have known abuse potential; moreover, there are concerns about possible
sensitizing effects of stimulants on the function and development of the brain reward system. Findings from
multiple preclinical studies demonstrate the potential of addictive drugs to alter brain organization in networks
involved in the processing of incentive motivation and reward30-38, and show that neuroadaptations that
accompany the development of addiction render the brain reward system hypersensitive (“sensitized”) to drugs
and drug-associated stimuli39. Moreover, animal studies have shown that stimulants enhance drug-
seeking/self-administration, whereas non-stimulants diminish those behaviors6,40. Similarly, human studies
have shown robust effects of stimulants on behavior41,42 and differential effects of methylphenidate (MPH) vs.
atomoxetine (ATX) on brain activation in the context of reward43.
Despite the above concerns, naturalistic studies have failed to consistently document an association between 
stimulant treatment and SUD risk - some have shown protective associations44-46, others predisposing 
associations47-49; and others no association50-52. Though it is tempting to conclude that there is little risk of SUD 
due to stimulant treatment, there is good reason to not summarily accept this conclusion. First, most existing 
studies have sample sizes of ~100 participants; this is insufficient to examine the association between 
stimulant treatment and SUD, which occurs at relatively low frequency even in high risk (HR) samples53. 
Second, longitudinal studies tend to under-recruit HR individuals – for instance the MTA sample had low rates 
of comorbid CD (e.g. 8%) compared to the 20-25% figure reported by others54. Third, longitudinal studies 
cannot randomly assign subjects to long-term medication vs. non-medication treatment due to ethical 
considerations, and there is inconsistent duration of exposure to medication and dose7. Fourth, naturalistic 
studies which pair clinical measures with imaging to assess the impact of treatment on the brain do not align 
the timelines for assessment and imaging with treatment – which means that they cannot specifically assess 
the impact of treatment. Most importantly, no study has examined the possible differential effects of stimulant 
treatment in youth with ADHD at relatively HR and low risk (LR) for SUD. This is problematic, because 
treatment might increase risk only in the subgroup of children who might be especially vulnerable. 
Yet, even if one accepts the importance of conducting a study of stimulant exposure and SUD risk, the 
question remains as to how to define risk and how to best measure it. While there is relative convergence 
regarding the importance of “reward sensitivity” and “sensitization to reward” as proxies of SUD risk, there is 
considerable disagreement about how to measure these constructs. A question of particular importance is 
whether to prioritize the study of behavioral or brain-based measures in relation to SUD risk. Of note, Robinson 
and Berridge6 argue that behavioral indices of sensitization are important only as secondary measures, to 
illustrate the consequences of underlying neuroadaptive processes linked to SUD. Other recent research has 
shown that imaging biomarkers and clinical factors may have different roles as predictors of treatment 
outcome55-57. Together, this evidence suggests that brain-based measures should be prioritized. Most 
importantly, it is thought that underlying physiological abnormalities can be indexed before the full development 
of the clinical phenotype9, meaning that these fMRI-derived biomarkers might be more sensitive to determining 
risk (i.e. before SUD onset). Thus, to best understand the neurobiological underpinnings of SUD risk, it is 
essential to study the effects of exposure to abusable substances on the brain reward system in youth who are 
naïve to such exposure, and examining possible differential effects in youth at relatively HR vs. LR for SUD.  
The examination of reward processing in ADHD has so far produced inconsistent results regarding which brain 
regions are activated by different reward tasks, and also the direction of activation in ADHD compared to 
controls. A number of studies have shown activation in NAcc during reward anticipation21,22  and reward 
outcome23,24 ; other regions have been indexed by reward outcome, including ACC25,26, orbitofrontal cortex 
(OFC)27,28, and insula18. Several small studies have reported that ADHD is associated with under-activation in 
ventral striatum (VS) and ventromedial prefrontal cortex (vmPFC)19, and negative correlations of activation with 
behavioral measures of impulsivity58. In contrast, a recent larger study in adolescents and young adults with 
ADHD found hyper-activation in VS20. Of note, reports  on activation changes in the brain reward system after 
Contact PD/PI: Newcorn, Jeffrey H
Research Strategy
Page 57
Effective Date: 12/19/2023
End Date:12/18/2024


administration of MPH have shown discordant findings; for instance Rubia et al. (2009)16 showed that MPH 
decreased baseline hyperactvation in OFC in ADHD while Minuzo et al. (2013)17 reported that MPH increased 
baseline hypoactvation in NAcc for ADHD vs controls. Most importantly, none of these reports have specifically 
examined subgroups of individuals with ADHD at HR vs LR for SUD, with the exception of one study from our  
group that showed higher activation in HR vs LR participants in the caudate and insula18.  In summary, the 
existing literature fails to demonstrate any consistent patterns of activation differences; individuals with ADHD 
may exhibit either higher or lower activation in a widely distributed set of brain regions, and the findings may 
differ in relation to reward anticipation or outcome.  Yet, existing studies have not separately examined 
individuals with ADHD at HR and LR for SUD. 
Summary. This study of drug-naïve youth at LR and HR for SUD studied pre- and post-treatment with 
amphetamine stimulants would provide important preliminary data for a larger scale investigation of reward-
related risk and protective effects of stimulants. fMRI will be used to determine whether brief treatment with 
stimulants yields differential effects on activation in the brain reward system in youth at HR vs. LR for SUD. 
Additionally, the degree to which changes in brain activation are linked to measures of ADHD and ODD/CD 
symptoms and reward sensitivity pre- and post-treatment will provide important information regarding the 
functional consequences of treatment. This proposal builds on two important and innovative characteristics 1) 
a strong translational paradigm; and 2) imaging techniques capable of quantifying functions in distributed 
neural circuits to index imaging biomarkers as indicators of treatment outcome. The goals of the proposed 
research are in concert with NIDA priorities which “encourage studies…to explore the relationship(s) between 
neural circuitry and treatment and prevention effects, and in particular, how behavioral targets might be 
affected by treatment and prevention interventions, and how that information might be used to improve 
targeted treatment and prevention intervention development, that translate to reduced morbidity and mortality.” 
B. INNOVATION The most innovative aspect of this proposal is its use of a translational design to investigate a
clinical question of considerable importance that cannot be answered using a more traditional longitudinal
approach. The decision to conduct a neuroimaging treatment trial of MAS-XR in drug-naïve LR vs. HR youth
with ADHD builds directly from findings in animal and human studies suggesting dysfunction in neural circuits
regulating reward processing, the observation that stimulants may be associated with potentially adverse
behavioral outcomes (i.e. increased drug self-administration6 and higher relapse rates in adults with ADHD
receiving stimulants42), and the recently articulated imperative to prioritize the study of biomarker predictors of
risk. This would be the first study to examine the influence of stimulant treatment on the brain reward system in
drug-naïve children at LR vs. HR for SUD, and thereby assess the neurophysiological basis of SUD risk in
these populations. Further, it will use a validated fMRI task (i.e., Anticipation, Conflict Reward (ACR)18), which
is developmentally sensitive and uses a novel approach to model reward mechanisms, including specific task
components to measure the potentially divergent effects of reward anticipation and outcome. We will further
examine changes in brain activation in relation to clinical symptoms and validated measures of reward
sensitivity obtained outside the scanner, which will allow us to more extensively determine the effects of
stimulant treatment on reward processing in context of clinical features. No study to date has explored changes
in the activation of the reward system in drug-naïve children with ADHD subdivided into those with relatively LR
and HR for later SUD, and related these changes in activation to behavioral/neuropsychological measures.
C. APPROACH.
C.1. Overview. The objectives of this study are to examine the effects of treatment with mixed amphetamine 
salts extended release (MAS-XR) on reward processing in youth with ADHD at HR and LR for SUD, and to 
delineate risk in relation to underlying neurobiological and clinical features. We will recruit 48 youth ages 7-12 
with ADHD+CD or severe ODD and treat 42 of these with MAS-XR for 3 weeks. We estimate a dropout rate of 
~15%, and expect 36 youth (18 per risk group) to complete treatment and 2 successful scans. Activation 
changes from baseline to end of treatment (EOT) in components of the reward system (e.g. VS, OFC, insula) 
will be assessed via fMRI. Ratings of ADHD symptoms will be obtained weekly; secondary neuropsychological 
and clinical measures of SUD risk will be obtained at baseline and EOT.
Successful completion of this study will illustrate the different effects of stimulant treatment (e.g. MAS-XR) on 
reward processing and activation during fMRI in youth with ADHD at HR vs. LR for SUD. We will make 
inferences regarding risk for substance abuse based on the presence or absence of differential effects of 
treatment on reward-related activation in relation to SUD risk status. If treatment produces similar changes in 
the reward system in participants at LR and HR, there should be no concern about increased risk for SUD with 
Contact PD/PI: Newcorn, Jeffrey H
Research Strategy
Page 58
Effective Date: 12/19/2023
End Date:12/18/2024


treatment. If treatment produces different activation profiles, this would raise questions about the suitability of 
this treatment in relation to SUD risk. Either way, the findings will inform a subsequent larger scale clinical 
translational study to more accurately determine the effects of stimulant treatment on SUD risk.   
C.2. Rationale for the Project Design
C.2.1. Rationale for Recruiting Children Ages 7-12. There are several advantages to working with 7-12 year 
olds with ADHD. First, studying the effects of stimulants in young, drug-naïve youth reduces the risk of both 
naturalistic exposure to drugs of abuse and stimulant treatment of ADHD (both of which are exclusionary). 
Further, our experience with fMRI studies in youth with ADHD suggests that by age 8 approximately 90% of 
participants can successfully complete both mock and actual scans. Age-related differences in the BOLD 
signal will be used as a covariate.
C.2.2. Rationale for Risk Group Definition. Studying LR vs. HR children will allow us to examine the effects of 
treatment on activation in the brain reward system as a function of risk status and determine whether MAS-XR 
may impact the reward system similarly or uniquely in HR vs. LR youth. Childhood ADHD has been associated 
with increased rates of drug abuse in adolescence; however, comorbid CD and severe ODD, which frequently 
co-occur with childhood ADHD, account for most of this association1. Therefore, children who have ADHD and 
CD or severe ODD (ODD + 2 symptoms of CD) will constitute the HR group. We will not require overt 
aggression, as this co-varies with CD and severe ODD. We considered requiring both FH and CD/severe ODD 
to define the HR group, but this would limit feasibility of recruitment. Moreover, CD has been found to be a 
better independent predictor of later substance abuse than FH of SUD in youth with ADHD59. Finally, choosing 
CD/severe ODD rather than FH to define the HR group offers an important clinical advantage, as stimulants 
are often used to treat ODD/CD symptoms in youth with ADHD8. Because the LR group cannot have + FH of 
SUD, we will exclude FH in first degree relatives in both the LR and HR groups (so the groups are balanced). A 
review of our MACRO sample shows that out of 90 youth with ADHD, 53 (57%) had comorbid ODD with no FH 
of SUD, which indicates that we will be able to recruit a sufficient number of HR youth for this study.
C.2.3. Rationale for the use of MAS vs. MPH.  All stimulants (e.g. MPH, MAS, cocaine) activate both the 
sympathetic and central nervous systems to heighten arousal, increase behavioral activation, and, when 
delivered rapidly to the brain, create a long lasting state of euphoria60. While similar, these effects differ 
between different classes of stimulants – e.g., existing evidence suggests that MPH-induced changes in brain 
dopamine and its metabolites are consistent with changes induced by other uptake blockers; however the 
magnitude of the dose-dependent increase in both the dopamine and norepinephrine responses for 
behaviorally comparable doses are considerably less than with amphetamine61. Therefore, we selected to use 
MAS for the current proposal due to: 1) stronger effects on brain chemistry that may be closer to the effects of 
drugs of abuse, and 2) potential use of AMP as replacement therapy in the treatment of cocaine abuse62.
C.2.4. Rationale for the Treatment Design. We propose an open label study of MAS-XR because the contrasts 
of interest are between the two SUD risk groups, and placebo is not needed. Available reports show BOLD 
changes with single dose stimulant challenge16,63 as well as different lengths of treatment64,64,65, with some 
reporting activation changes after 3 weeks of treatment66. Therefore we expect that 3 weeks is a sufficient 
amount of time to show changes on fMRI; it is also not too long to substantially increase cost and risk for 
dropout. In our prior experience with MPH/ATX comparison trials, the dropout rate was 18% for a 4-month 
protocol and 10% for a 6-week protocol. Ideally we might have included a control group to assess practice 
effects, but that would be prohibitive for the scope and budget for this proposal. Data from 4 subjects who did 2 
scans with the ACR task without interventions showed no appreciable practice effects.
C.2.5. Rationale for Use of the Anticipation, Conflict, Reward (ACR) task.  The fMRI task to be used in this 
protocol (ACR) was developed by Dr. Jin Fan (co-I) and piloted by our group. The task has several important 
features: 1) it is developmentally appropriate, and the value of using child-friendly designs to help keep 
children engaged has been amply recognized67; 2) it balances task length and the requisite number of different 
events (e.g., cues, flankers, reward outcomes), thus decreasing burden and maximizing task completion; 3) it 
has a novel unexpected non-reward component that can be used to conduct exploratory analyses of reward 
processing in relation to negative outcomes (i.e., negative prediction error); and 4) it has been shown to 
successfully index changes in activation in the brain reward system in relation to stimulant administration63.
C.3.  Feasibility of Study Design (includes preliminary studies).
C.3.1. Qualifications. The team has an extensive record of research on the neurobiology and pharmacotherapy
Contact PD/PI: Newcorn, Jeffrey H
Research Strategy
Page 59
Effective Date: 12/19/2023
End Date:12/18/2024


of ADHD, as well as expertise in the use of fMRI to examine activation in the reward system in youth with 
ADHD and varying SUD risk. The consultants are acknowledged experts in imaging substance abuse risk.
C.3.2. Capacity to Recruit the Sample. Dr. Newcorn’s team has an established record of recruiting youth with
ADHD who are scanned pre- and post-treatment, and has published one of the very few treatment studies in
ADHD directly comparing MPH and ATX using fMRI59. We have also successfully recruited drug-naïve youth
with ADHD at HR and LR for SUD.   
             
Figure 1. 
C.4.2. Inclusion criteria: 1) General: pre-pubertal (e.g. Tanner stage 1 or 2), age 7-12 inclusive, signed 
consent/assent, parent communicates sufficiently in English; 2) ADHD: ADHD as determined by computerized 
DISC (C-DISC) parent interview69, ADHD-Rating Scale-5 total score (interview with parent)70 and SNAP71 
ADHD total score (teacher rating) of 1.5 SD > age/sex norms; 3) CD or severe ODD: CD or ODD + 2 
symptoms of CD on C-DISC; SNAP ODD/CD subscale (parent and teacher) 1.5 SD > age/sex norms. 
Exclusion criteria: 1) major neurological/medical illness; 2) history of head injury; 3) fetal exposure to 
alcohol/drugs; 4) diagnosis of major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major 
depression, generalized anxiety, social phobia, Tourette’s Disorder, PTSD, autism spectrum disorder); 5) 
current suicidal ideation or past history of suicide attempt; 6) Wechsler Abbreviated Scale of Intelligence 
(WASI)72 score <75; 7) prior or current treatment with stimulants (prior or current treatment with non-stimulants 
is permitted, but participants must be off medication for 2 weeks at baseline); 8) current or past alcohol/drug 
use (DISC interview; urine toxicology); 9) psychological or medical condition which precludes being in the 
scanner (e.g., claustrophobia, morbid obesity); 10) metal in the body that cannot be removed; 11) visual 
disturbances that may impair task performance; 12) precocious puberty (e.g. Tanner stage >2).
C.4.3 Study Periods
Study Period I: Screening/baseline (Visits 1–2). The 1st and 2nd visits both involve assessment; the 2nd visit also 
includes the baseline fMRI scan. Subjects will have a “mock scan” at the 1st visit, following established 
guidelines76. We anticipate that the assessment procedures can be completed in 2 study visits within 14 days. 
The screening period can be lengthened to accommodate washout of a non-stimulant drug if this is required. 
Study Period II: 2 Week Treatment Block (Days 0 to 21). Subjects will receive open label treatment with MAS-
XR for 3 weeks. Medication will be titrated using a fixed dose approach, with doses that mimic those used in 
clinical practice. The two assigned doses are 0.25 mg/kg and 0.5 mg/kg, with an option to increase to 1.0 
mg/kg if needed. At study completion, participants will complete the post-treatment fMRI scan and all clinical 
measures. There will be 2 visits during this period - one after 1 week of treatment and one at 3 weeks (EOT). 
There will be a phone visit at the end of the second treatment week, though subjects can be seen if necessary.  
C.4.4. Study medication and medication administration. Subjects treated with non-stimulants will be required to 
be off medication for 2 weeks prior to the scan. We will purchase MAS–XR, an extended release generic 
amphetamine formulation. Subjects will begin at 0.25 mg/kg and increase to 0.5 mg/kg after one week. This 
dose can be reached (within ~5 mg) using 2 capsules of commercially available doses. Those who cannot 
increase the dose due to AEs will be allowed to maintain their dose and be evaluated for a dose increase after 
2 weeks. Subjects who experience difficulty with symptom control can titrate to a higher dose if need be 
(maximum 1 mg/kg). Subjects who increase their dose and experience AEs will be allowed to lower their dose. 
Subjects will receive MAS–XR on the day of the second scan approximately 6-8hrs before scan.
C.3.3. Preliminary Studies. Our publications show that the ACR
task can successfully recruit regions within reward network
during reward outcomes and that reward-related activation is
elevated in youth at HR for SUD18. We have also successfully
treated and scanned youth with ADHD treated with MPH vs.
ATX68. New data show demonstrable higher activation in HR vs
LR/controls in insula, ACC and putamen during Unexpected
Non-reward outcome of the ACR (Figure 1).
C.4.  Methods and Procedures. C.4.1. Sample. We will recruit
48 prospective subjects and randomize 42 who meet
inclusion/exclusion criteria and complete the baseline fMRI scan
to treatment with MAS-XR (21 per group). We budget for ~15%
dropout per group leaving a total of 18 per group with completed
assessments and scans.
Contact PD/PI: Newcorn, Jeffrey H
Research Strategy
Page 60
Effective Date: 12/19/2023
End Date:12/18/2024


C.4.5. Measurement and Management of Adverse Effects (AEs). AE ratings will be collected at baseline and 
each medication visit, using open-ended reporting and the Barkley stimulant side effect scale73. We also 
monitor for changes in pulse and blood pressure, and suicidal behavior (see below). All AEs are logged and 
reported to the IRB; profiles of AEs are reviewed by the DSMB annually.  We have conducted similar trials 
using stimulants for years and have never had to modify the protocol due to AEs.
C.4.6. Data Management. Demographic and clinical data will be recorded on paper forms, de-identified, and 
translated to a Microsoft access database. MRI data will be uploaded to the Mount Sinai High Performance 
Computing system, identified by number only; imaging data will be backed up to a hard drive.
C.5. Description of Tests and Procedures
C.5.1 Measures to Characterize the Sample. KSADS or C-
DISC)69 (~45-90 minutes).  The C-DISC and KSADS assesses current and past psychopathology according 
to DSM criteria. Dimensions of psychopathology. Child Behavior Checklist (CBCL)74 (~30 minutes). The 
CBCL is a validated and well-established broad-band parent-report scale, which will be used to characterize 
the sample. ADHD Rating Scale-5 (ADHD-RS). Investigator interview with parent (~15-20 minutes); teacher 
report70.  SNAP ODD/CD (parent/teacher)71 (~5-10 minutes); The SNAP is a comprehensive 90 item 
rating scale for ADHD and ODD/CD. It will be used to operationalize inclusion criteria for the ADHD children 
and serve as a measure of treatment response. To minimize burden we will use only the ODD and CD items. 
Symptom Severity: Clinical Global Impressions - Severity Scale (CGI-S)75 (~2 – 5 minutes). The CGI is a 
clinician rated 7-point scale completed by the clinician based on review of all available information. The 
companion CGI-Improvement scale (CGI-I) will be used to rate improvement from baseline to end of treatment. 
Wechsler Abbreviated Scale of Intelligence for Children (WASI)72 (~20 minutes). Substance Use. Urine 
toxicology will be obtained at baseline to ensure that no substances of abuse are being used by the child. 
Prenatal exposure to alcohol/drugs, assessed via the Pregnancy and Birth Questionnaire76 (completed by 
the parent) (~5 min). Family History of psychiatric disorders and SUD. Family History Assessment Module 
(FHAM)77 (~25 min) is a semi-structured diagnostic interview conducted with the parent. Medical Status. We 
obtain height, weight, hand dominance78, sexual development assessed by Tanner self-report scale for 
puberty79 and a physical examination at baseline. We screen for individual and family cardiovascular risk, and 
obtain additional consultation as necessary, including ECG, to document of safety for study participation. 
C.5.2.Tolerability: ASSERS [Barkley Stimulant Side Effect Rating Scale73] (~5 minutes). Columbia Suicide 
Severity Rating Scale (C-SSRS)80 (~5 minutes). Heart rate and BP (~5 minutes) and open ended 
report of AEs and concomitant medications (~2-5 minutes) will be obtained at baseline and each treatment 
visit (weeks 1–6).
C.5.3  Secondary (Behavioral) Measures: Behavioral Inhibition/Activation Scale (BIS/BAS)81 (~10–15 minutes) 
is a validated 20-item scale that has been shown to correlate with activation in reward circuits82. Kirby Delay 
Discounting Task83 (~10–15 minutes) is a validated test which assesses temporal (delay) discounting; the 
temporal discount parameter has been shown to correlate with the activation in the reward brain circuitry in 
adolescents84. UPPS Impulsive Behavior Scale consists of 45 items using a 4-point Likert scale and has 4 
subscales: Urgency, Lack of Premeditation and Perseverance and Sensation Seeking785.
C.6. Study timeline
Timeline of study recruitment
Year 1
Year 2
Total
 Subjects Screened
N = 24
N = 24
N=48
Subjects Randomized
N = 21
N = 21
N=42
Subjects Completed 2 scans
N = 18
N = 18
N=36
C.7. Neuroimaging Methods
C.7.1. Neuroimaging Procedures. Equipment. The Siemens 3T MAGNETOM Skyra is an FDA approved 3
Tesla human MRI scanner. It has a short and open bore (173 cm system length with 70 cm Open Bore
Design). The magnet is equipped with actively shielded echo-planar capable Siemens (SONATA) whole-body
gradient coils and Siemens CASCADE gradient amplifiers. A Siemens 32ch head coil is also available for
improved signal-to-noise ratio in the cortical area, and increased parallel imaging capability.
Contact PD/PI: Newcorn, Jeffrey H
Research Strategy
Page 61
Effective Date: 12/19/2023
End Date:12/18/2024


C.7.2. Task paradigms. The ACR is an event-related task that provides 3 temporally distinct probes of reward
anticipation, conflict resolution, and reward outcome. It consists of four 32-trial blocks, each 6 minutes long.
There are 2 cue types (reward/non-reward) followed by congruent/incongruent flankers: both cue and flanker
trials are counterbalanced and are fully orthogonal. Participants are required to respond as quickly as they can
to the direction of the central arrowhead while ignoring the flankers. Correct responses in trials beginning with
reward cues yield $1 reward. Incorrect or slow responses are followed by a $1 loss. The ACR task provides
only 25% money wins and introduces reward violation (unexpected non reward) in 25% of the trials, which
results in strongly engagement of the insula, ACC and also putamen predominantly during reward outcomes.
C.8. Data Analysis
C.8.1. First level (within-subject) analyses will be conducted for each participant with a general linear model
(GLM) to quantify the relationship between the observed event-related BOLD signals and regressors encoding
expected trial-specific responses. The design matrix will be comprised of 12 regressors: 2 for cue (reward vs.
non-reward) x 2 for target type (congruent or incongruent flankers) x 3 for outcome-related effects (reward,
non-reward, punishment). There are 4 outcome contrasts of interest: reward following reward cue, non-reward
following reward cue, non-reward following non-reward cue, or punishment for an incorrect/missing response.
C.8.2.  Group-level Statistical Analysis.  Descriptive statistics (e.g., means, standard deviations (SD), etc.) for
all variables of interest will be computed and compared by Student t test for continuous variables or Chi-square
test for categorical variables. Group statistical analyses of the imaging data will be performed using a GLM
from SPM. The GLM is written as Y=XB+E, where Y is a matrix with a series of multivariate measurements, X
is a design matrix, B is a matrix containing parameters that are usually to be estimated and E is a matrix
containing errors or noise. The errors are usually assumed to follow a multivariate normal distribution86,87.
Primary Aim. Hypotheses 1a) HR will show greater activation than LR at baseline will be tested via F-test of the 
voxel-based whole brain activation with one-way ANCOVA with group (HR, LR) as the between-subjects 
factor; age, sex, and IQ are nuisance covariates.: 1b) MAS-XR treatment will reduce activation in both groups, 
with greater magnitude of change in HR youth, will be tested via F-tests with ANCOVA of the voxel-based 
whole brain activation controlling for time (baseline, post-treatment) with groups (HR, LR) with age, sex, IQ and 
medication dose as covariates. We will use t-tests to examine 1) differences in activation at baseline and 2) 
activation differences at end of treatment between HR and LR in specific ROIs. The voxel-based Z statistic 
images will be thresholded using clusters determined by Z>2.3 and a cluster corrected significance threshold 
of p<0.05. 
Exploratory Aim.  We will conduct correlation analyses between pre to post- treatment measures of activation 
in the reward system and scores on the behavioral measures collected outside the scanner (i.e., Kirby, 
BIS/BAS, UPPS) to examine the direction and magnitude of correlations between brain function and behavior. 
C.8.4. Power analyses. The main power considerations for the primary aim are related to the ability to detect
differences in activation between the two groups pre- to post treatment. We estimated power using Monte
Carlo simulations (10,000 draws per model), with α = 0.05, for all models. With a between subjects factor (2-
levels; LR, HR) and 4 covariates (age, sex, IQ, dose level), we were able to recover large effects sizes (f = .80-
1.0) for the between group factor with 40 ADHD subjects, which corresponds to approximately a .8-1 difference
in activation. For the exploratory aim, we used regression models with the behavioral measures, the same 4
covariates, using the baseline level of each behavioral measure to control for time effects and activation as the
dependent variable.  In the simulations, we were able to recover effect sizes of d =.2-3 with 4-5 independent
nuisance covariates (age, sex, IQ, does), and baseline covariates with a correlation of .35 in the model.
C.8.5. Expected outcomes/interpretation of findings. Reduced reward-related activation after treatment with
MAS-XR would suggest that the drug may reduce SUD risk by decreasing hypersensitivity to reward; this
finding should be amplified by ratings and test measures of reward sensitivity and related constructs obtained
outside the scanner. The degree of correlation between brain activation and behavioral measures will inform as
to which behavioral scales are most appropriate to use in our planned R01.
C.8.6. Potential problems.  It is possible that treatment with MAS-XR will yield activation changes in the
opposite direction from what was hypothesized – i.e., increased rather than decreased activation in the HR
group. Although against the hypothesis advanced here, this finding would be of considerable interest, as it
would suggest that stimulants might be associated with increased rather than decreased risk of SUD in youth
at HR for SUD. This would then become the subject of a subsequent large scale study.
Contact PD/PI: Newcorn, Jeffrey H
Research Strategy
Page 62
Effective Date: 12/19/2023
End Date:12/18/2024


PHS Human Subjects and Clinical Trials Information
OMB Number: 0925-0001 and 0925-0002
Expiration Date: 03/31/2020
Tracking Number: GRANT12677775
Funding Opportunity Number: PA-18-344 Received Date:
2018-07-16T12:51:37.000-04:00
Are Human Subjects Involved
●Yes
❍No
Is the Project Exempt from Federal regulations?
❍Yes
●No
Exemption Number
❏1
❏2
❏3
❏4
❏5
❏6
❏7
❏8
Other Requested Information
Contact PD/PI: Newcorn, Jeffrey H
Page 63
Effective Date: 12/19/2023
End Date:12/18/2024


Tracking Number: GRANT12677775
Funding Opportunity Number: PA-18-344 Received Date:
2018-07-16T12:51:37.000-04:00
Human Subject Studies
Study#
Study Title
Clinical Trial?
1
Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder
Yes
Contact PD/PI: Newcorn, Jeffrey H
Page 64
Effective Date: 12/19/2023
End Date:12/18/2024


OMB Number: 0925-0001 and 0925-0002
Expiration Date: 03/31/2020
Tracking Number: GRANT12677775
Funding Opportunity Number: PA-18-344 Received Date:
2018-07-16T12:51:37.000-04:00
Section 1 - Basic Information (Study 1)
1.1. Study Title *
Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder
1.2. Is this study exempt from Federal
Regulations *
❍Yes
●No
1.3. Exemption Number
❏1
❏2
❏3
❏4
❏5
❏6
❏7
❏8
1.4. Clinical Trial Questionnaire *
1.4.a. Does the study involve human participants?
●Yes
❍No
1.4.b. Are the participants prospectively assigned to an intervention?
●Yes
❍No
1.4.c. Is the study designed to evaluate the effect of the intervention on the
participants?
●Yes
❍No
1.4.d. Is the effect that will be evaluated a health-related biomedical or
behavioral outcome?
●Yes
❍No
1.5. Provide the ClinicalTrials.gov Identifier (e.g.
NCT87654321) for this trial, if applicable
Contact PD/PI: Newcorn, Jeffrey H
Page 65
Effective Date: 12/19/2023
End Date:12/18/2024


Tracking Number: GRANT12677775
Funding Opportunity Number: PA-18-344 Received Date:
2018-07-16T12:51:37.000-04:00
Section 2 - Study Population Characteristics (Study 1)
2.1. Conditions or Focus of Study
❍
ADHD
2.2. Eligibility Criteria
1) General: pre-pubertal (e.g. Tanner stage 1 or 2), age 7-12 inclusive, signed consent/assent, parent communicates
sufficiently in English; 2) ADHD: ADHD as determined by computerized DISC (C-DISC) parent interview, ADHD-Rating 
Scale-5 total score (interview with parent) and SNAP ADHD total score (teacher rating) of 1.5 SD > age/sex norms; 3) CD or 
severe ODD: CD or ODD + 2 symptoms of CD on KSADS; SNAP ODD/CD subscale (parent and teacher) 1.5 SD > age/sex 
norms. Exclusion criteria: 1) major neurological/medical illness; 2) history of head injury; 3) fetal exposure to alcohol/drugs; 4) 
diagnosis of major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, generalized anxiety, social 
phobia, Tourette's Disorder, PTSD, autism spectrum disorder); 5) current suicidal ideation or past history of suicide attempt; 
6) Wechsler Abbreviated Scale of Intelligence (WASI) score <75; 7) prior or current treatment with stimulants (prior or current 
treatment with non-stimulants is permitted, but participants must be off medication for 2 weeks at baseline); 8) current or 
past alcohol/drug use (DISC interview; urine toxicology); 9) psychological or medical condition which precludes being in the 
scanner (e.g., claustrophobia, morbid obesity); 10) metal in the body that cannot be removed; 11) visual disturbances that 
may impair task performance; 12) precocious puberty (e.g. Tanner stage >2).
2.3. Age Limits 
Min Age: 
7 Years
Max Age:
12 Years
2.4. Inclusion of Women, Minorities, and Children
R21_Inclusion of women and minorities-March.pdf
2.5. Recruitment and Retention Plan
Subject Recruitment and Retention.pdf
2.6. Recruitment Status
Not yet recruiting
2.7. Study Timeline
Study timeline.pdf
2.8. Enrollment of First Subject
07/01/2020
Anticipated
Contact PD/PI: Newcorn, Jeffrey H
Page 66
Effective Date: 12/19/2023
End Date:12/18/2024


Inclusion of Women, Minorities, and Children
Inclusion of Women 
There are no gender restrictions for this study; we will recruit both males and females. Due to the gender 
distribution between males and females with ADHD diagnosis in youth, we expect a somewhat larger number 
of males (estimate between 3 males to every 1 or 2 females). We expect the gender ratio to more heavily favor 
males in the group with ADHD + CD/severe/ODD, and to be more balanced in the ADHD only group. The 
control group will be recruited to reflect the age and sex characteristics of the clinical sample.
The sex ratio of the parents who will provide assessment information about their children (and also their 
families) will be 75 - 90% female. Although ~50% of our cases have a father or father figure who is involved, 
and although encourage participation from both parents (especially during the baseline and end of treatment 
assessments), we most often only see the mother. Ongoing medication visits are almost always conducted 
with the mother and child. In rare circumstance, a father or grandfather will be the primary contact and 
informant, although in those instances we also solicit information from the mother.  
Inclusion of Minorities 
Because we are located in a large urban area, there is ample minority representation.  Findings from previous 
research studies conducted by our team indicate that the ethnicity of our participants is approximately 40% 
Hispanic, 30% African-American, 20% Caucasian and 10% of Asian or mixed ancestry. It is expected that a 
similar representation will be seen in the proposed study.  The sample is also likely to vary with regard to 
socioeconomic status (SES).  Using the Hollingshead’s scale (Hollingshead, 1975) for rating SES, the median 
SES in our samples is 4, though participants span the full range from 1 - 6. This SES distribution closely 
matches the ethnic and SES make-up of the region in New York City where the research is being conducted.  
Inclusion of Children
The participants in this study will be children and pre-pubescent adolescents.  Our specific age range 
(7-12) was guided by our team’s experience conducting fMRI studies in youth with ADHD and risk for 
substance abuse. By adolescence, there is a growing risk of substance abuse and potential for pregnancy 
among females with behavioral problems (both exclusory condition) and thus a significantly increased 
risk of attrition at screening.  
Contact PD/PI: Newcorn, Jeffrey H
Inclusion of Women, Minorities, and Children
Page 67
Effective Date: 12/19/2023
End Date:12/18/2024


Subject Recruitment and Retention.  Participants in the two groups will be recruited from 
multiple sources, including the Mount Sinai Child and Adolescent Psychiatry Outpatient clinics 
(see letter from Dr. Liu), community-based programs (see letters from Mrs. White,), the Mount 
Sinai General Pediatric Clinic, and the Center for Addictive Disorders (see letter from Dr. Hurd). 
Dr. Newcorn’s previous experience with imaging adolescents with ADHD indicates that, by 
using telephone pre-screening, it is possible to limit the number of enrolled subjects who are 
“screen failures” to 15% - either because they don’t meet the study criteria or because they 
cannot perform the fMRI scans. We have not had difficulty recruiting normal controls for 
neuroimaging protocols; we anticipate the need to recruit 35 to obtain a final n of 30 controls 
with completed assessments and an fMRI scan. All together, we anticipate pre-screening a total 
of ~60 youth with ADHD in order to enroll 48 at-risk subjects.  We have built in an estimated 
15% attrition rate in the treatment trial, mainly due to poor tolerability or lack of response. This 
number is based on our current experience in fMRI treatment studies in youth with ADHD, 
including a randomized parallel group fMRI treatment study of atomoxetine and 
methylphenidate. However, we will over-recruit if we do not meet our expected end of treatment 
numbers. We expect that given our history of successful recruitment of children with ADHD and 
paid advertising, we should be able to reach the final number of 36 participants at risk (i.e. 18 
per cell) with full clinical and fMRI data at baseline and post-treatment. We anticipate being able 
to evaluate 3 new participants per month and randomize 2 subjects per month.
A variety of methods are used to enhance recruitment and retention. Families are compensated 
for their time in participating in the research. All subjects receive a comprehensive evaluation, 
including a variety of clinical and neuropsychological assessment measures, which can be 
useful for school placement or obtaining accommodations. They receive treatment with an 
approved medication for ADHD without risk of randomization to placebo. They will receive case 
management services during the trial. In case of sub-optimal response or poor tolerability in the 
trial, they can receive open treatment with a medication of their choice after the trial. And they 
can often be referred to after-care within our clinical treatment programs. 
Contact PD/PI: Newcorn, Jeffrey H
Recruitment and Retention Plan
Page 68
Effective Date: 12/19/2023
End Date:12/18/2024


Study timeline
Timeline of study recruitment
Year 1
Year 2
Total
 Subjects Screened
N = 24
N = 24
N=48
Subjects Randomized
N = 21
N = 21
N=42
Subjects Completed 2 scans
N = 18
N = 18
N=36
Contact PD/PI: Newcorn, Jeffrey H
Study Timeline
Page 69
Effective Date: 12/19/2023
End Date:12/18/2024


Tracking Number: GRANT12677775
Funding Opportunity Number: PA-18-344 Received Date:
2018-07-16T12:51:37.000-04:00
Inclusion Enrollment Reports
IER ID#
Enrollment Location Type
Enrollment Location
Study 1, IER 1
Domestic
Icahn School of Medicine at Mount Sinai
Contact PD/PI: Newcorn, Jeffrey H
Page 70
Effective Date: 12/19/2023
End Date:12/18/2024


Tracking Number: GRANT12677775
Funding Opportunity Number: PA-18-344 Received Date:
2018-07-16T12:51:37.000-04:00
Inclusion Enrollment Report 1
Using an Existing Dataset or Resource* :
❍Yes
●No
Enrollment Location Type* :
●Domestic
❍Foreign
Enrollment Country(ies):
USA: UNITED STATES
Enrollment Location(s):
Icahn School of Medicine at Mount Sinai
Comments:
Planned
Racial Categories
Ethnic Categories
Not Hispanic or Latino
Female
Male
Hispanic or Latino
Female
Male
Total
American Indian/
Alaska Native
0
0
0
0
0
Asian
1
1
0
1
3
Native Hawaiian or
Other Pacific Islander
0
0
0
0
0
Black or African
American
4
5
1
4
14
White
3
9
2
3
17
More than One Race
1
4
2
7
14
Total
9
19
5
15
48
Cumulative (Actual)
Racial Categories
Ethnic Categories
Not Hispanic or Latino
Female
Male
Unknown/
Not
Reported
Hispanic or Latino
Female
Male
Unknown/
Not
Reported
Unknown/Not
Reported Ethnicity
Female
Male
Unknown/
Not
Reported
Total
American Indian/
Alaska Native
0
0
0
0
0
0
0
0
0
0
Asian
0
0
0
0
0
0
0
0
0
0
Native Hawaiian or
Other Pacific Islander
0
0
0
0
0
0
0
0
0
0
Black or African
American
0
0
0
0
0
0
0
0
0
0
White
0
0
0
0
0
0
0
0
0
0
More than One Race
0
0
0
0
0
0
0
0
0
0
Unknown or
Not Reported
0
0
0
0
0
0
0
0
0
0
Total
0
0
0
0
0
0
0
0
0
0
Contact PD/PI: Newcorn, Jeffrey H
Page 71
Effective Date: 12/19/2023
End Date:12/18/2024


Tracking Number: GRANT12677775
Funding Opportunity Number: PA-18-344 Received Date:
2018-07-16T12:51:37.000-04:00
Section 3 - Protection and Monitoring Plans (Study 1)
3.1. Protection of Human Subjects
Protection of Human Subjects.pdf
3.2. Is this a multi-site study that will use the same protocol to
conduct non-exempt human subjects research at more than one
domestic site?
❍
Yes
●
No
❍
N/A
If yes, describe the single IRB plan
3.3. Data and Safety Monitoring Plan
Data Safety Monitoring Plan Nov 17.pdf
3.4. Will a Data and Safety Monitoring Board be appointed for
this study?
●
Yes
❍No
3.5. Overall structure of the study team
Overall Structure of the Study Team.pdf
Contact PD/PI: Newcorn, Jeffrey H
Page 72
Effective Date: 12/19/2023
End Date:12/18/2024


5. Potential Risks to the Subjects.
There are several potential risks to participation in these studies. This study involves collection
of interview and self-report questionnaires, neuropsychological testing and having a magnetic
resonance imaging scan. It also involves administration of medication to youth with ADHD.
While fMRI and the ratings are deemed to be minimal risk, any study involving the
administration is deemed to be more than minimal risk. ADHD subjects will have potential for
benefit by having a thorough structured clinical evaluation, and receiving treatment with an FDA-
approved medication. Aspects of the testing protocol may prove beneficial to healthy controls,
although the battery is not designed to specifically benefit this group. The potential risks are:
5.1.  Clinical trial  
There is some risk to participation in the trial, since children and adolescents will receive 
treatment with MAS-XR which is commercially available FDA - approved treatment for ADHD. 
Common side effects include: insomnia, loss of appetite, irritability, headache, occasional 
dysphoria, and tics. Other more serious adverse effects such as palpitations and increased 
heart rate have been documented. 
It is inevitable that in a study such as this, which includes treatment of youth with ADHD, with 
one subgroup deemed to be at high risk for SUD based on the presence of a comorbid 
disruptive behavior disorder, there may be problems which require management (emergency or 
otherwise). For routine management issues of the sort to be expected with this population, we 
are providing case management. For problems related to medication tolerability or safety, the 
treatment visit window can be shortened to as little as three days if tolerability at any dose of 
either medication is poor. For more emergent problems, we will utilize a version of the MTA 
(Multimodal Treatment Study of Children with ADHD) ASAP (i.e., Adjunct Services, Attrition 
Prevention) manual93. The ASAP manual lays out a procedure for assessing crisis situations, 
and allows for a pre-determined number of non-directive, supportive counseling sessions to help 
patients and families respond to crises. To address potential problems from lack of response to 
the study medications (both are FDA-approved and, in general, are considered to be quite 
effective for treating ADHD, but some individuals may not respond to or tolerate the rug to which 
they are randomized), we will offer open treatment after the completion of the randomized trial, 
using any treatment approach that seems indicated.  If none of the above methods are 
successful in managing the problem, we will encourage subjects to discontinue the trial if it is 
not in their best interest to remain as participants. 
Emergent events need not be related to the trial. One example is real or perceived child abuse, 
maltreatment or neglect. Current ongoing abuse or neglect is an exclusionary criterion for the 
study. However, if abuse is suspected after enrollment, we will, as mandatory reporters, make a 
report to the appropriate agency. Suspicion of abuse will not necessarily be grounds for 
dismissal from the study (depending on the situation), but confirmed abuse will result in 
termination from the study.  
The other potential risks and discomforts for subjects are, in general, minimal. No discomfort is 
expected with psychological examinations or clinical interviews. 
Additional risks are related to confidentiality of personal information. Every effort is made to 
protect confidentiality. All individual information obtained will be held strictly confidential. No 
information that might in any way lead to the identification of the source will be made public. All 
raw data from the study will be kept in locked files and identified by ID number only; names, 
addresses, and any other identifying information of study individuals or families will be kept in an 
entirely separate, locked location. The consent forms will be stored in a separate and secure 
location from data obtained using the other data collection methods. All study data will be used 
Contact PD/PI: Newcorn, Jeffrey H
Protection of Human Subjects
Page 73
Effective Date: 12/19/2023
End Date:12/18/2024


for research purposes only and retained at a minimum until the research project is completed. 
All study personnel will receive Human Subjects and HIPAA training to ensure compliance with 
IRB and research ethics guidelines. Electronic data will be protected on a secure server behind 
a firewall and in accordance with HIPAA regulations. All PHIs will be stored on a SQL server 
with access permitted on the basis of need. 
5.2.  fMRI study and procedures  
We will examine critical SU-relevant domains with a novel and validated tasks that will allow us 
to provide a neurocognitive profile across our domains of interest that target pathways to SUD. 
All children will perform the Anticipation, Conflict, Reward (ACR) task; we estimate that the fMRI 
sessions, including the structural scans required for co-registration, will require about 40 
minutes to complete. We will use the MRI facilities of the Mount Sinai Translational and 
Molecular Imaging Institute. Images will be acquired on a Skyra 3.0 Tesla magnet using a 
gradient echo T2*weighted echo planar imaging (EPI) (See Approach section) with a blood 
oxygen level dependent (BOLD) contrast. All MRI procedures combined will require 
approximately 1 hour of scan time. Based on our experience and feedback from similar 
populations, the imaging tasks are considered fun and enjoyable, and do not induce distress. 
There are very few potential risks to participation.   The MRI scan requires the participant to lay 
still with his/her head in a tunnel-like device.  The procedure is painless and not uncomfortable. 
A small proportion of participants (about 3%) have difficulty tolerating the procedure because of 
claustrophobia.  If a participant becomes upset by the procedure, the study will be terminated.  
There is no evidence that MRI is in any way harmful or has adverse effects.  The Food and 
Drug Administration (FDA) has set recommendations for exposure in MRI studies and this study 
satisfies those criteria.  Persons not suited for this study include those who have cardiac 
pacemakers, neural pacemakers, surgical clips in the brain or blood vessels, surgically 
implanted metal plates, screws or pins, cochlear implants, or metal objects in their body, 
especially in the eye.  Dental fillings do not present a problem. Some subjects find the loudness 
of the oscillating gradients during image acquisition to be discomforting, but the noise level is 
below FDA guidelines of 140 dB peak referenced to 20 micropascals. In addition subjects are 
provided with ear plugs and headphones to reduce the noise. 
We manage the risks of having an MRI scan in several ways. We offer practice on the task 
outside the scanner before the scan, and have the child warm up to the experience of being in 
the MRI scanner by having a “mock scan” before the actual scan takes place. This provides the 
child experience with the scanner environment, including lying inside the MRI tube and 
performing the task, and accommodating to the noise which is typical of this procedure. 
There also are potential risks from the tasks, which are in general minimal.  The animation used 
in the ACR task offers neutral images that are unlikely to be upsetting to participants, however, 
all participants will be shown a subset of comparable stimuli outside the scanner and will be 
exposed to practice versions of the task they will undergo in the scanner and are provided with 
the opportunity to withdraw from the study if they find the task aversive.
6. Adequacy of protection against risks.
6.1.  Vulnerable subjects:
6.1.1. Children. Children are considered to be vulnerable subjects; therefore, the Mount Sinai 
Medical Center Certification of Assent procedure will be used.  The investigator will explain the 
protocol to the child in a developmentally appropriate manner.  If the child agrees to participate, 
he/she will be asked about the protocol by an independent individual, who is not related to the 
child and is not involved in the study (e.g., a clinic nurse, clinician; administrative assistant; or 
staff from other research groups).  This individual will certify in writing that the child indeed 
Contact PD/PI: Newcorn, Jeffrey H
Protection of Human Subjects
Page 74
Effective Date: 12/19/2023
End Date:12/18/2024


understands the protocol and assents to participation (and that this assent is free of coercion). If 
assent is not obtained, evaluation will not commence even if the parent consents.  In addition, 
the clinicians and other personnel involved in this study will be trained in the management and 
interviewing of children. 
6.1.2. Financially disadvantaged persons.  The study population is expected to include subjects 
from all financial and social strata.  We will not exclude a subject based on financial parameters 
nor will we ask for a payment for the evaluation.  The reimbursement (for baseline assessment 
and two scans) for subjects’ time is enough to cover transportation fees and a lunch at 
the time of the interview, but is not coercive in that it does not constitute an 
unreasonably high incentive for participation - even for financially disadvantaged persons. 
6.2.  Recruitment.  Participants and their parents will be clearly told that participation in the 
present study is voluntary and that they can choose not to participate and still receive treatment 
in the Mount Sinai clinic or another treatment facility of their choosing.  We also aim to reduce 
the boredom of the fMRI scan by using child-friendly tasks, which appeal to the child’s potential 
interest in doing the scan when they are considering whether or not to participate, and maintain 
the child’s interest in performing the tasks properly during the procedure. Pilot data from other 
fMRI treatment studies we have conducted in youth with ADHD indicate that we can recruit the 
requisite number of youngsters for studies using fMRI, and that the majority are interested in 
participating and would participate again if asked. In addition, very few children who can 
successfully complete the scan ask not to do the procedure again. 
6.2.1. Informed Consent.  Participants will be pre-screened prior to the first visit to inform the 
adolescents and caregivers about the research trial and to identify basic inclusion/exclusion 
criteria. If participants wish to enroll in the study, consent forms will be sent to the home so the 
caregivers can review them. Enough time is given for the caregiver to read the consent form 
and discuss it with a family member or the current care provider, if so desired.  Prior to the 
initiation of study procedures, the consent form is read and explained to the participant and his 
or her caregiver by the investigator or a delegate.  The consent form includes the purpose and 
description of the study procedures as well as the potential risks and discomforts, 
cost/reimbursements, 
compensation 
for 
injury, 
confidentiality, 
voluntary 
participation, 
alternatives to participation, potential termination of participation, financial disclosures of 
interest, and names of contact persons. Following a review of the consent form, all participants 
and their caregivers will be queried about distinct aspects of the study, and the time involved in 
the various procedures, to ensure they were paying attention to the description of the 
procedures and understood what they heard and read in the consent document.  After a 
thorough description of the research, including the risks and benefits and the alternatives to 
participation, the parent or caregiver is asked to sign the consent form if they freely consent to 
the procedures of the study.  The caregiver will also sign Health Insurance Portability and 
Accountability Act (HIPAA) forms, which indicate to the caregiver how information regarding the 
participant is disclosed. A witness, not associated with the research study team, will meet with 
the adolescent independently and sign and date the MSSM “Certification of Assent of Minor” 
form to document that the child freely assented to participate. The MSSM Certification of Assent 
form is used for ALL children, regardless of age, to document assent was freely given without 
coercion.  The caregiver and the research study delegate obtaining the consent will sign the 
consent form.
6.2.2.  Compensation. 
All participant payments are in keeping with IRB approved levels and are generally at the low 
end of payment practices for similar participation in the US. To reimburse the families for 
time away from work we will pay compensation for the completion of the fMRI scan in the 
amount of $50
Contact PD/PI: Newcorn, Jeffrey H
Protection of Human Subjects
Page 75
Effective Date: 12/19/2023
End Date:12/18/2024


The average payout for the tasks is ~$20. All in-person interview payments and earnings from 
the tasks (won and to be paid on the same day) will be paid on the day of the interview 
either in cash or gift certificate. Depending on IRB requirements, children/youth may 
receive gift certificates instead of cash, or a combination of cash and gift certificates the 
day of their visits. We will offer compensation for public transportation in the amount of 
$20 per visit. 
6.3.  General Procedures.
6.3.1.  Psychological risks. The clinical scales and psychometric instruments used in this 
study are primarily standardized, commonly-used instruments. Many are used in clinical 
practice but others are more specific to the research setting. Most children experience the 
testing sessions as fun, although a small proportion may find the tests boring or tedious. The 
child or the parent may feel discomfort while talking to the clinician about adverse life 
events and traumatic experiences.  The subjects will be explicitly told that they can stop 
answering questions or terminate the interview at any time. The interviews and the consent 
procedure will take place in a dedicated room, not in the waiting area, so that subjects would 
feel less compelled to answer questions or to “behave”.  When indicated, children who 
will not feel safe alone will be interviewed together with the parent.
6.3.2  Discovery of previously unreported abuse:  This will be discussed immediately with 
the participant and family and reported as indicated and in accordance with NY State law.  
Cases will be managed immediately by a board certified child psychiatrist, who is a 
member of the research team or when indicated, by another care provider. The child will not be 
discharged until safety is established in accordance with prevailing clinical practice.  In 
cases where safety cannot be established, the child will be taken for further evaluation in the 
pediatric emergency room.
6.3.3.  Suicidal or homicidal ideation revealed during the course of evaluation:  A board certified 
child psychiatrist, who is a member of the research team, will evaluate the child and 
if necessary, the adolescent will be taken to the emergency room for additional 
evaluation.  Although the PI will assist in this procedure, the primary decision with respect 
to possible hospitalization will be made by the clinical consultation/liaison team, which 
conducts the emergency room evaluation, and not by the research team. This will ensure 
that all decisions regarding management reflect the clinical needs of the participant, and not 
any considerations in relation to the research. 
6.3.4.  Discovery of a previously unknown psychiatric disorder during evaluation:  If safety 
is compromised or could potentially be compromised, the information will be reviewed with 
the family by the Co-PIs or one of the Co-Is. If there is no threat to safety and the newly 
discovered disorder represents a contraindication to participation (e.g., the discovery of a Major 
Depressive Disorder with no psychotic features and no suicidality), the parent and the 
child will be counseled accordingly and encouraged to seek help.  If the parent agrees 
to seek further treatment, a referral for further evaluation will immediately be made.  Research 
participants can often be seen for a reduced fee in the child psychiatry outpatient clinic. 
A range of other potential sites for clinical follow-up will also be offered. Participants referred 
to clinical services within Mount Sinai will receive standard-of-care treatment, which may 
include psychotherapy or medications. Decisions related to possible treatments will be made 
by the clinician(s) at the outpatient clinic, or other clinical site.
6.3.5.  Management of transient anxiety that may be caused by the questionnaires/procedures: 
This will be managed immediately by the research team, including attempts to better understand 
the source of the problem, and to provide acute intervention as required. Should any 
Contact PD/PI: Newcorn, Jeffrey H
Protection of Human Subjects
Page 76
Effective Date: 12/19/2023
End Date:12/18/2024


intervention be made by the research team, the participant/family will not be responsible for 
payment for this intervention.  It is very unlikely that more than one brief session will be needed 
for the treatment of anxiety caused by the questionnaires, should it occur.  However, in the case 
of pre-existing psychopathology that may make any anxiety which arises more resistant to 
intervention, the child will either be immediately evaluated by the consultation/liaison team or 
referred to the Mount Sinai outpatient clinic. Participation in the study will be suspended if this 
occurs, and not resumed unless and until the child and family agree to continue the research 
evaluation, and the evaluating clinician agrees that proceeding with the research evaluation is 
not contraindicated.
6.3.6. Positive urine toxicology: Both parent(s) and child will be informed during the informed 
consent procedure that a urine toxicology test will be part of the initial evaluation, and that if 
there is a positive finding, the result of the test will be revealed to both the child and the parent. 
If this occurs, the PI or other qualified team members (e.g. child psychiatrist, psychologist) will 
counsel the family and discuss options for further action. Since positive urine toxicology is an 
exclusionary criterion for study participation, participants who have positive urine toxicology 
tests will be discontinued from the study. 
6.4.  Clinical trial.   
6.4.1. General Issues. All interviewers will receive thorough and rigorous training on all aspects 
of interview administration, confidentiality, subject recruitment and acceptable methods of 
interviewer-subject interaction. All responses will be held confidential, to the extent permitted by 
law, including from the treatment/court authorities and other family members. Interviewees will 
be informed that reports or observations of suspected child abuse may require reporting to Child 
Protective Services and that information about other possible threats to the child (such as 
suicidality) may need to be reported to parents/guardians. Parents and youth are informed 
before the start of the interview that any threat of harm to or by a minor child will have to be 
reported to the parent and that any threat of child abuse or homicidal threat must be reported to 
the appropriate authorities. Parents will be told of any serious threat or harm to their child. All 
limits to confidentiality will be explained to all participants and their parents during the consent 
process. Even though the participants read the consent/assent forms, the specific sections of 
the consent form addressing these issues will be read to parents and children. Specifically, they 
will be told that we will protect the participant's confidentiality and that we will not share any 
personal information collected. Parents will be explicitly informed that they cannot have access 
to any of the research self-report data, including information collected about their child's 
substance use or other high risk behaviors, unless their child is in imminent danger and/or it is 
clinically determined that they need an intervention that requires parental consent.
6.4.2. Medications.  The medication to be used in this study is FDA-approved for the treatment 
of ADHD. While some would argue that stimulants are more effective in both risk groups to be 
studied, others would argue that non-stimulants might be preferable, either as a general rule or 
specifically in high risk subjects. As a rule, non-stimulants are considered a more appropriate 
first choice in youth who are currently abusing drugs, but there are no guidelines about whether 
to use stimulants or non-stimulants in children with ADHD + comorbid ODD/CD. Many would 
say that stimulants are more effective and should be used in this population; others might favor 
non-stimulants. It is clear that there is room for both clinical judgment and the different opinions 
held by clinicians and parents with regard to medication selection in the treatment of youth with 
ADHD. However, with specific regard to randomization in this study, stimulant medication is 
indicated in the subject groups being treated and appropriate to use. 
6.4.3. Dose titration. We use an escalating, dose-optimizing approach that incorporates 
measures of clinical response and tolerability, and is maximally responsive to the clinical needs 
Contact PD/PI: Newcorn, Jeffrey H
Protection of Human Subjects
Page 77
Effective Date: 12/19/2023
End Date:12/18/2024


of participants. If there is inadequate response and tolerability is excellent the dose will be 
increased. If response is deemed to be excellent (and tolerability at least good), the dose will be 
maintained. If an initial excellent response is not maintained, the dose can be increased. 
Likewise, if the medication is not adequately tolerated, we will either maintain the dose (i.e., 
allowing additional time to accommodate) or lower the dose. If tolerability improves, we will 
increase the dose until optimal response is reached (i.e., CGI-S rating of 1 or 2).
6.4.4. Monitoring and managing problems in titration. Children will be monitored closely during 
the study, with weekly visits during medication titration and treatment. The interval between 
visits and the schedule of dose changes can be altered if clinically warranted. For example, if 
there is a problem with tolerability or an adverse event that prevents dose escalation, the 
pharmacotherapist can maintain or lower the dose. If titration is slowed in order to 
accommodate to adverse effects, but tolerability is subsequently achieved, the duration of the 
trial can be extended. In addition, the visit window can be increased or decreased (by 3 - 4 days 
in either direction) as clinically warranted.   
6.4.5. Clinical emergencies: Clinical emergencies are defined as any situation where a subject 
expresses or shows: 1) potential for harmful behavior (to self or other), such as suicidal ideation 
or behavior or threat of violence/homicide; 2) serious emotional distress; or 3) impairment of 
reality testing (e.g., unable to communicate coherently, illogical response, hallucinations). If a 
subject manifests behaviors that constitute a clinical emergency either during an interview or at 
another time, the principal investigator and appropriate clinical staff will be contacted 
immediately and provide a thorough review of the situation. If it is deemed that further or 
additional interventions are required that cannot be offered by the study, an appropriate referral 
will be made. This study also uses a procedure called ASAP (Adjunct Services/ Attrition 
Prevention) utilized in the Multimodal Treatment Study of Children with ADHD93, which offers 
two sessions of supportive, non-directive counseling and/or problem solving for patients who 
experience difficulties in the trial, which require emergent intervention but do not reach the 
threshold for referral to an outside provider. Often, this procedure helps youth and parents to 
make a plan during an immediate crisis period, without having to drop out of the trial.  However, 
we will encourage participants to drop out if there are substantive clinical problems of an 
emergent or time sensitive nature that cannot be addressed within the trial. 
6.4.6. Discontinuation from the study:  Subjects may withdraw at any time or be withdrawn 
should contraindications to continued participation develop. Subjects will be terminated early if 
there is: 1) Intolerance to study drug that cannot be managed by dose reduction; 2) worsening 
of symptoms which poses serious risks to the subject or others; 3) significant medical or 
psychiatric complications, even if not related to the study drug. 
6.4.7. Poor Adherence:  We track medication dispensed, taken and returned at each visit.  
Subjects who are non-adherent are counseled regarding proper use of the medication. Subjects 
who are repeatedly non-compliant may be withdrawn from study. In our experience, this rarely is 
necessary. 
6.4.8. Dropouts:  Subjects who do not complete at least 3 weeks of randomized medication are 
considered dropouts. Subjects who prematurely discontinue the trial will be encouraged to 
complete their fMRI scan.
6.4.9.  Clinical Support/Back-up:
As in all our studies, we routinely have clinical back-up available, so that if necessary, a 
psychiatric consultation can be arranged immediately, especially in cases of suicidal or 
homicidal concern. All interviewers will be thoroughly trained in appropriate response to 
reported or otherwise presented clinical issues. Also, during MRI procedures, Drs. Newcorn and 
Contact PD/PI: Newcorn, Jeffrey H
Protection of Human Subjects
Page 78
Effective Date: 12/19/2023
End Date:12/18/2024


Ivanov (Co-PIs on this protocol) will be available for immediate consultation, if necessary. In 
cases of suspected abuse, the interviewer will obtain specific information, which will then be 
transmitted to the Principal Investigators, who will consult and decide what action must be 
taken. We will also provide all study parents with a list of local mental health/substance abuse 
services and family support organizations. 
We have a well-established protocol for addressing situations that may indicate an issue of 
clinical concern, or which may pose a threat of harm to either the youth or the parent. If a threat 
of harm to the child is reported, the parent will be told before leaving the Study Center. If the 
threat is urgent (e.g., current suicidality or threat of violence), one of the study clinicians may be 
called directly to intervene. If need be, the family may be referred to the Mount Sinai emergency 
room. All cases involving past or present threat of harm to a minor child (e.g., suicidality, 
bullying), even if help has been obtained, are discussed with the parent. In all cases of clinical 
concern, interviewers must fill out a clinical report before leaving the Study Center and, if the 
issue is not urgent, must contact the appropriate study administrators within 24 hours of the 
interview. If there is some additional concern, the interviewer contacts the administrator 
immediately after the interview. Administrators then contact the study team clinicians, who then 
call the family directly. In cases of suspected abuse, the Principal Investigator(s) will consult and 
decide to see what action should be taken. In cases where a participant may become distressed 
during the interview, they will be offered the opportunity to stop the interview for a while or, if 
they wish, to complete the interview at another time. If they wish, they can also speak with one 
of the study administrators and/or clinicians.
Drs. Newcorn and Ivanov (the study Co-PIs) have established relations with the Child 
Psychiatry Consultation Liaison, the Psychiatric ER and the Child and Adolescent inpatient 
services and will personally facilitate the needed assessment and procedures including 
emergency room evaluations to establish child’s safety and possible emergency admissions if 
that is indicated. 
In addition, our team has developed a network of referral sources for youths in need for 
treatment, including both prevention and treatment agencies within the Mount Sinai Health Care 
system and in the larger New York City area. Therefore, any individual case of reporting and/or 
manifesting a need for prevention or treatment services would get individually tailored referral 
meeting his/her and the family needs. 
6.5.  Risks associated with MRI scanning:  There are few serious risks associated with the 
MRI procedure.  The best protection against these risks is having a well-trained staff who are 
comfortable working with children and who are familiar with MRI procedures and working in the 
imaging environment.  Participants will be carefully screened to insure that they have no metal 
implants or other characteristics that would preclude MRI scanning.  In addition, prior to the 
scan, all metal jewelry, body piercings, hairclips, belts, etc. will be removed, as well as, wallets, 
keys and any other objects that represent a potential risk in the highly magnetized MRI 
environment.  Staff will also be well-versed in ethical standards and will be instructed that if a 
participant wants to terminate the study, that is what should be done.  We use cartoon images 
as stimuli during the functional scans, and play cartoons or movies for the children during 
anatomical scans.  This tends to increase the level of engagement. The children will enter the 
scanner in the presence of their parents, and the procedures will be explained to them while 
they are being prepped for scanning. In addition, participants will be given time to acclimate to 
the scanner. There is always at least one member of the study staff present with a child during a 
scan; in cases where scanning is anticipated to be less easily negotiated, 2 staff members may 
be present. Parents often remain in the scanner area to calm and reassure the children during 
the scans. However, this is rarely required.  Finally, participants will have had an opportunity to 
acclimate to the fMRI procedures prior to the day of the scan through participation in a “mock 
Contact PD/PI: Newcorn, Jeffrey H
Protection of Human Subjects
Page 79
Effective Date: 12/19/2023
End Date:12/18/2024


scan” procedure – which simulates the fMRI experience.  
The MRI portion of the study presents possible minimal risks. Though for most people the MRI 
presents very few physical risks, certain factors may increase the risk. MRI scanning has been 
demonstrated to have potentially negative effects when performed on people who have metal-
based tattoos (although this is not a problem with recently obtained tattoos), transdermal 
patches, or metallic objects or electronics that cannot be removed (for instance, metal fillings, 
internal electronic devices, etc.). Persons with such risk factors (except non-reactive tattoos) 
must be appropriately screened and excluded from completing the study because participation 
might be dangerous for them. For those subjects who do not possess the above 
contraindications for scanning, the risks posed from MRI scanning are of two types: 1) potential 
discomfort or distress during scanning, and 2) the possibility of anatomic abnormalities being 
discovered in the course of scanning (See #5 below). The first risk—fear or discomfort from 
scanning—is generally greater for young people than for adults. However, we are very 
experienced in scanning children, and we have developed a very child-friendly facility and 
scanning protocol. Still, it is possible that some subjects might experience minor distress by the 
confined and noisy conditions in the scanner. This possibility will be minimized, first by 
introducing children to the MRI using a mock scanner, where the rules for the tasks will be 
explained and the experience of being in a scanner will be simulated (e.g. playing scanner 
noises) to acclimate the child to the scanner environment. Other strategies include requirement 
of inserting ear protective devices, using a mirror that enables a view outside the scanner, and 
using experienced technicians who will monitor all subjects for distress and reassure 
participants when necessary. In the event that a participant becomes anxious during a scan, the 
study will be halted. Participants will be able to communicate with the technician at all times 
using the intercom system should they have concerns or questions during the procedure or to 
request that a scan be terminated or suspended. The subject will be in full view of the operator 
at all times. Additionally, participants with fear of enclosed spaces will be excluded from the 
study. 
The risks from the scanner itself can be classified into one of five categories: a) Acoustic Noise 
Levels, b) Gradient or Time-Varying Magnetic Fields, c) Radiofrequency (RF) Magnetic Fields, 
d) Static Magnetic Fields, and e) Other.
i) Acoustic Noise Levels: The acoustic noise associated with MR imaging is related to the
mechanical movement of the gradient coils during the scanning process. The acoustic noise
levels perceived by human subjects when undergoing MRI examination in our 3.0 Tesla magnet
constitutes a non-significant risk; specifically, our system will not be operated in a way that will
present more noise to human subjects than is recommended by the FDA and ear protective
device will be used at all times.
ii) Time-Varying Magnetic Fields: The concern about the time-varying magnetic fields used in
MRI is that these can, in some instances, induce stimulation of peripheral nerves, thereby
producing sensations such as 'twitching' or 'tingling.’ In very rare instances, this nerve
stimulation can be painful. The gradients used in our Skyra 3.0 Tesla MRI system will typically
be operated at levels below those considered to be negligible according to FDA guidelines. Our
system, like most commercially available, FDA-approved systems, does have the capacity to
exceed this level, but it will include the same safeguards that are included in other FDA-
approved clinical systems. Furthermore, policies and procedures will be implemented according
to FDA guidelines to avoid the possibility of painful peripheral nerve stimulation. Therefore, in all
circumstances the system will be operated in a way that poses non-significant risk to the
participant.
iii) Specific Absorption Rate (SAR): MRI scanning induces some heating of body tissues. This
specific absorption rate (SAR) that determines heating is the amount of radiofrequency (RF)
Contact PD/PI: Newcorn, Jeffrey H
Protection of Human Subjects
Page 80
Effective Date: 12/19/2023
End Date:12/18/2024


energy deposited (typically by a coil or “helmet”-like apparatus placed over the subject’s head) 
per Center volume of tissue per Center time. The SAR for RF radiation is primarily related to the 
amplitude of RF power, the duration of the RF pulse, the type of RF coil used, the frequency of 
RF radiation, the resistivity of the tissue, the configuration of the anatomical region being 
examined, and several other parameters. FDA Guidelines: "The following are levels of concern 
at which the reviewer shall exercise appropriate actions to ensure that the safety of the device is 
substantially equivalent to a predicate device: A) If SAR = 0.4 W/kg whole body; and if SAR= 
8.0 W/kg spatial peak in any 1 gram of tissue; and if SAR = 3.2 W/kg averaged over the head: 
below level of concern. Or B) If exposure to radiofrequency magnetic fields is insufficient to 
produce a core temperature increase in excess of 1°C and localized heating to greater than 
38°C in the head, 39°C in the trunk and 40°C in the extremities: below level of concern. The 
parameter SAR cited above must be shown to fall below either of the two levels of concern by 
presentation of valid scientific measurement or calculation evidence sufficient to demonstrate 
that SAR is of no concern."  Because all experiments performed on the 3.0 Tesla system will 
comply with FDA guidelines with regard to SAR, and because appropriate RF power safety 
checks are in place, this criterion for classification of NSR is satisfied.
iv) Static Magnetic Fields: The possible risks of static magnetic fields have received much
attention in the lay press, but scientific consensus on these risks has yet to be fully reached.
The FDA has deemed that systems operating at 8.0 Tesla or less do not pose a significant risk.
Moreover, experience with thousands of clinical studies over the past decade, and with multiple
human investigations carried out at higher field strengths over this period, have not revealed
risks of exposure to higher static magnetic fields. The most significant risk associated with static
magnetic fields is that ferromagnetic objects, such as aneurysm clips or heart valves, can
interact with the magnetic field of an MRI scanner, causing the device to malfunction or to move,
and injuring the subject. Children with these objects will be identified, as described above, and
excluded from the scan.
This category of risk applies to work conducted around superconducting magnets of any kind 
(including standard clinical diagnostic MRI Centers). It is not unique to our 3.0 Tesla facility, 
which will maintain a safety policy to safeguard subjects and staff members from these 
incidental risks. Systems with static magnetic field less than 8 Tesla have been considered to 
represent a non-significant risk by the FDA. The static magnetic field of our system (3.0 Tesla) 
is therefore to be classified as posing non-significant risk to human subjects.
v) Other Potential Risks: The physical confinement and isolation produced by the scanner could
cause emotional distress, although in our past experience, subjects generally tolerate the
procedures well.
vi) Incidental findings on MRI: Another possible risk stems from incidental findings that might be
detected during scanning. The probability of an incidental finding that might lead to the
diagnosis of an unknown abnormality is greater than zero. All subjects will be alerted to this
possibility during the consent process. Though the type of scan used does not, in general, give
adequate information for a clinical quality-read (of which subjects will be informed), if the MRI
technologist or experimenter sees something concerning, a radiologist will read the scan for
potential gross abnormalities and will report any such findings to the PI, so that the subject may
be notified in a timely and appropriate fashion. If an incidental finding arises, parents will be
advised to consult with their child’s physician for further evaluation.
If a subject is injured as a result of participation in this research study, emergency care, 
hospitalization, and outpatient care will be made available by The Mount Sinai Health Care 
system and billed to the subject/family as medical expenses. No money will be provided by the 
Institute as compensation for a research-related injury. See also “Protection against Risk” 
below.
Contact PD/PI: Newcorn, Jeffrey H
Protection of Human Subjects
Page 81
Effective Date: 12/19/2023
End Date:12/18/2024


6.6. IRB Approval. Several steps are taken to protect against a breach of confidential 
information.  The collection, use, and sharing of information will adhere to HIPAA regulations, 
and participants and their parents will be required to sign IRB-approved statements that the 
HIPAA regulations have been explained to them.  This applies to personal health information 
collected by both the Departments of Radiology and Psychiatry.  Participants’ names, dates of 
birth, and other identifying information collected during the proposed study will be stored in 
source documents.  The source documents will be stored in locked file cabinets in the PI’s 
locked office.  
Information (e.g., rating scales, diagnostic interviews) from the clinical 
assessments obtained as part of the study will also be stored in the source document folders.  
Information from the source documents pertinent to the research (e.g., age, diagnosis. etc.) will 
be entered into and stored in databases.  These databases will not contain identifying 
information and will be indexed by a research code. Data from the fMRI procedures will be 
downloaded to the study team, or put onto compact discs provided to the PI or his designee. 
The compact discs will be stored in the locked file cabinet with the source documents.  The 
images from the compact discs will be transferred to a fixed location computer that is password-
protected.  These computers are connected to the internet through the MSSM network.   The 
images will be indexed by the same research code and contain no identifying information.  
Computer files containing the data from the fMRI tasks are created with the research code only 
and contain no identifying information.  These computer files will be stored on the same fixed 
location computer.  The research codes will be stored in the participants’ source document, 
thereby providing a link between the research data and the identifying information.  Only the PI 
and the research coordinators working on this project have access to the source documents and 
the link between the identifying information and research codes.
The study team will obtain Mount Sinai IRB approval and will adhere to all IRB guidelines for 
protection of human subjects. 
6.6.1. External review.  Risks to confidentiality also include the possibility of outside review of 
participant charts by members of the DSMB or by ethical or governments organizations wishing 
to review charts for data verification purposes. This is explained in the consent form. 
6.6.2. Sources of Materials.  Behavioral, psychiatric, neuropsychological and neuroimaging data 
will be collected from children and adolescents.  All data collected within the context of this 
research will be used for research purposes only.  Results of the neuroimaging procedure will 
be used for research purposes only.  Structural scans can be made available to qualified 
professionals, when appropriate, and with the written consent of the participants and their 
parents.  
Contact PD/PI: Newcorn, Jeffrey H
Protection of Human Subjects
Page 82
Effective Date: 12/19/2023
End Date:12/18/2024


Study oversight and DSMB.  Human subject protection will be ensured by the routine procedures that we 
have put in place to conduct the study, and also the oversight which is provided by the Data Safety Monitoring 
Board (DSMB). The DSMB will review all aspects of the study, including recruitment procedures, informed 
consent, protocol violations, the occurrence and handling of adverse events, and patient outcomes. This 
information will be provided for review by the senior study coordinator. The DSMB will review this information in 
blinded fashion; randomization codes will only be examined if there is serious consideration of altering the 
study design in any way. The DSMB review protects subjects because it oversees the implementation of good 
clinical and research practices, and monitors the safety of the trial. The DSMB will meet annually and write a 
report to describe its findings. This report will be shared with the site PIs and filed with the IRB. 
6.7.1. Data and Safety Monitoring Plan
a) External DSMB
A DSMB will be put in place to review the conduct and safety considerations of the trial.
b) Composition of the DSMB
The committee for the clinical trial will consist of two clinical researchers who are not directly involved in this 
project and who have no stake in the outcome of the study. The two members of the DSMB will be 
psychiatrists who have extensive experience with clinical trials with stimulant and non-stimulant medications for 
ADHD, and expertise in incorporating fMRI biomarkers into these trials. DSMB members will be compliant with 
OMB guidelines, will not be employees of Icahn School of Medicine at Mount Sinai, and will have no conflict of 
interest with this research.
c) Procedures and Responsibilities of the DSMB
Two to four weeks prior to each DSMB meeting, the senior coordinator and data manager will prepare a report 
to be reviewed during that meeting, under the direction and supervision of the PIs. The report will include the 
number of participants who signed consent for the study and were randomized, the number of post-
randomization dropouts, reasons for these dropouts, and any safety concerns, adverse events, etc. An up-to-
date consent form will be provided, as well as a summary of measures taken to protect confidentiality (e.g., 
data and tape storage, use of coded ID numbers, etc.)  The Study Coordinators will also prepare a report 
summarizing any new data/evidence that might alter the risk/benefit ratio for participating in the study (e.g., 
newly published studies, etc.)  Data will be presented to the DSMB in such a way as to maintain patient 
confidentiality.
The DSMB will meet via conference call yearly.  At an initial meeting, the DSMB will review the research 
protocol and plans for data and safety monitoring. The DSMB will issue an annual report that summarizes:
(1) All serious and unexpected adverse events (for example, inpatient hospitalizations or ER weeks) or other
unanticipated problems that involve risk to study participants or others, and whether these appeared related to
the study-based interventions or research assessment protocols. Reports will not specifically disclose the
treatment arm of the study unless this disclosure is required for safety reasons.  Note that any serious adverse
event (SAE) will be reported to the local IRBs and to the DSMB within a 24 hours according to standard
regulations.
(2) The committee’s judgments as to whether participants’ safety, privacy, and confidentiality have been
consistently assured by the investigators;
(3) The committee’s review of the study’s progress toward recruitment goals and participant retention/attrition
rates;
(4) Its review of new scientific literature pertinent to the safety of participants or the ethics of research
participation (for example, new therapeutic or imaging developments);
(5) Its recommendations as to whether risk/benefit ratios have changed to the extent that the trial should be
modified or discontinued. Specific recommendations for protocol modifications will be elaborated, with the
accompanying rationale for each.
The DSMB reports will be filed with the PIs, who will file them immediately with the IRB. This information is also 
included in the annual progress report to NIH. The reports will enumerate the dates that the committee met and 
its explicit procedures for monitoring participants’ safety and confidentiality, and data integrity during the 
Contact PD/PI: Newcorn, Jeffrey H
Data and Safety Monitoring Plan
Page 83
Effective Date: 12/19/2023
End Date:12/18/2024


reporting interval.
There will be regular, ongoing communication between the PIs, the IRB, and the DSMB.  The PIs will take 
responsibility for reporting any serious and unexpected adverse events in a timely fashion directly to the 
DSMB.  The PIs will also report serious and unexpected adverse events or other unanticipated study problems 
to the IRB.  Actions taken by IRB in response to adverse event reports will be immediately reported to the 
DSMB and the NIH Project Officer, if appropriate.   
The Mount Sinai IRB (FWA Assurance Number 0005656) will review all required documentation (initial and 
annual renewal applications, recruitment materials, adverse event reports, etc.) for the Mount Sinai site in this 
project. 
6.8. Safety Monitoring Plan:  This protocol presents minor increase over minimal risk to the subjects. The 
medications to be used in the study are well-established and considered to be safe; serious adverse events 
are not anticipated. In the unlikely event that such events occur, they will be reported in writing within 24 hours 
to the local IRB. The initial SAE report will be followed by submission of a completed SAE report to both 
institutions. In the event that a participant either withdraws from the study or the investigator decides to 
discontinue a participant due to an SAE, the participant will be monitored by the investigator via ongoing status 
assessment until 1) a resolution is reached, i.e., the problem requiring hospitalization has resolved or stabilized 
with no further changes expected, 2) the SAE is determined to be clearly unrelated to the study intervention, or 
3) the SAE results in death. Outcome of SAEs will be periodically reported to NIDA. A summary of the SAEs
that occurred during the previous year will be included in the annual progress report to NIH.
The PIs will be responsible for evaluating the adverse events and study data at regular intervals and determine 
whether the adverse event affects the Risk/Benefit ratio of the study and whether modifications to the protocol 
or consent form are required. During the review process, the PIs will evaluate whether the study should 
continue unchanged, require modification/amendment, continue or close to enrollment. Either the PIs or the 
IRB have the authority to stop or suspend the study or require modifications. The review of all adverse events 
by the PIs will determine the attribution and grade of severity of the adverse event by using the following 
scales:
Attribution of Risk Categories.
Definite: Adverse event(s) will clearly be related to investigational agent(s) or other intervention
Probable: Adverse event(s) will likely be related to investigational agent(s)
Possible: Adverse event(s) may be related to investigational agent(s)
Unlikely: Adverse event(s) will doubtfully be related to investigational agent(s)
Unrelated: Adverse event(s) will clearly not be related to the investigational agents(s)
Grades of Risk.
0: No adverse event or within normal limits
1: Mild adverse event
2: Moderate adverse event
3: Severe adverse event resulting in hospitalization or prolongation of existing hospitalization, a persistent or   
significant disability/incapacity, or a congenital anomaly/birth defect 
4: Life-threatening or disabling adverse event
5: Fatal adverse event
6. Clinicaltrials.gov Requirements
The proposed study does not meet the requirements as an applicable clinical trial.
Clinicaltrials.gov Requirements.
The proposed study meets the requirements for an applicable clinical trial. Once approved, the study will be 
posted in clinicaltrials.gov. Updates will be provided as appropriate.
Contact PD/PI: Newcorn, Jeffrey H
Data and Safety Monitoring Plan
Page 84
Effective Date: 12/19/2023
End Date:12/18/2024


Overall Structure of the Study Team
Qualifications. The team has an extensive record of research on the neurobiology and 
pharmacotherapy of ADHD, as well as expertise in the use of fMRI to examine activation in the 
reward system in youth with ADHD and varying SUD risk. Drs. Newcorn and Ivanov have an 
established record of recruiting youth with ADHD who are scanned pre- and post-treatment, and 
has published one of the very few treatment studies in ADHD directly comparing MPH and ATX 
using fMRI. We have also successfully recruited drug-naïve youth with ADHD at HR and LR for 
SUD. Drs. Shulz and Fan have been close collaborators with the PIs on this project as evident 
from our publication record. They will provide expertise on quality control and analyzing of the 
neuroimaging data.  
Contact PD/PI: Newcorn, Jeffrey H
Overall Structure of the Study Team
Page 85
Effective Date: 12/19/2023
End Date:12/18/2024


Tracking Number: GRANT12677775
Funding Opportunity Number: PA-18-344 Received Date:
2018-07-16T12:51:37.000-04:00
Section 4 - Protocol Synopsis (Study 1)
4.1. Brief Summary
Children with attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder (ODD) and conduct disorder (CD) 
 are known to have elevated risk for adolescent-onset substance use disorders (SUD), and those with comorbid ADHD + 
 ODD/CD are at greatest risk.  Stimulant medications such as extended release mixed amphetamine salts (MAS-XR) and 
 non-stimulant medications (e.g. atomoxetine or guanfacine) have established efficacy for ADHD and are also beneficial for 
 ODD/CD. However, stimulants have direct effects on the brain reward system, and abnormal reward processing is thought to 
 mediate addiction vulnerability. Although longitudinal studies have not shown increased SUD risk in youth with ADHD treated 
 with stimulants, it remains unknown whether stimulants might have differential effects on reward processing in high risk (HR) 
 vs. low risk (LR) populations.   
fMRI offers a cost effective method of evaluating covert effects of stimulant medications for youth with ADHD and SUD risk by 
 examining pre- to post-treatment changes in activation in the brain reward system that predate exposure to drugs of abuse. 
 This approach is supported by the results of studies, which indicate altered (mostly elevated) sensitivity in the reward system 
 in youth at-risk for SUD; high activation in the reward system has in turn been linked to problem drug use. However, to date, 
 no study has examined changes in the reward system with stimulant treatment in youth with ADHD and high vs. low risk 
 for SUD, who have never been exposed to stimulant treatment or drugs of abuse. Such research could provide important 
 knowledge regarding the biological basis of addiction vulnerability and guide treatment selection.        
Our team is in an excellent position to study differences in activation in the brain reward system during fMRI before and after  
treatment with MAS-XR in young children (7-12 years old) with ADHD, who are naïve to both stimulant treatment and drugs  
of abuse, divided into LR (i.e., ADHD only) and HR (i.e., ADHD + ODD/CD) groups. We will confirm that youth with ADHD/HR 
status have exaggerated activation in the reward network compared to ADHD/LR youth and controls, and test competing  
hypotheses regarding the effects of the two medications on the brain reward system, and across the different risk groups.  
This protocol is innovative in its approach to study young, drug-naïve children at various levels of SUD risk, and is highly  
significant in its use of neuroimaging to delineate possible differential effects of stimulant and non-stimulant medications on  
reward processing in youth with ADHD and HR vs. LR for SUD as a biomarker of treatment-related risk. This research will  
substantially advance our understanding of the biological basis of vulnerability for addiction, and aid in the development of  
treatment recommendations for youth with ADHD and varying levels of SUD risk.
4.2. Study Design
4.2.a. Narrative Study Description
Childhood ADHD and comorbid oppositional defiant disorder (ODD) and conduct disorder (CD) are considered risk 
 factors for subsequent substance abuse, and youth with both ADHD and ODD/CD are at greatest risk. However, the 
 effects of treatment of ADHD with stimulant medications such as methylphenidate (MPH) and mixed amphetamine salts 
 (MAS) on risk for substance abuse are poorly understood. We propose to use fMRI to study the effects of extended  
release mixed amphetamine salts (MAS-XR) in drug-naïve youth 7-12 years at low risk (i.e., ADHD only) and high risk  
(i.e., ADHD + ODD/CD) for substance abuse on the brain reward system, to better understand the potential impact of  
these medications on an aspect of brain functioning which is thought to underlie vulnerability to substance abuse.
4.2.b. Primary Purpose
Prevention
4.2.c. Interventions
Type
Name
Description
Drug (including
placebo)
Mixed Amphetamine Salts
This is an FDA approved treatment for ADHD
4.2.d. Study Phase
Phase 4
Is this an NIH-defined Phase III Clinical Trial?
❍
Yes
●
No
4.2.e. Intervention Model
Single Group
4.2.f. Masking
❍
Yes
●
No
❏Participant
❏Care Provider
❏Investigator
❏Outcomes Assessor
Contact PD/PI: Newcorn, Jeffrey H
Page 86
Effective Date: 12/19/2023
End Date:12/18/2024


Tracking Number: GRANT12677775
Funding Opportunity Number: PA-18-344 Received Date:
2018-07-16T12:51:37.000-04:00
4.2.g. Allocation
N/A
4.3. Outcome Measures
Type
Name
Time Frame
Brief Description
Primary
fMRI activation during a
behavioral 'ACR' task
Pre and Post 3 weeks
C.7.2. Task paradigms. The ACR is an event-
related task that provides 3 temporally distinct
probes of reward anticipation, conflict resolution,
and reward outcome. It consists of four 32-trial
blocks, each 6 minutes long. There are 2 cue
types (reward/non-reward) followed by congruent/
incongruent flankers: both cue and flanker trials
are counterbalanced and are fully orthogonal.
Participants are required to respond as quickly as
they can to the direction of the central arrowhead
while ignoring the flankers. Correct responses in
trials beginning with reward cues yield $1 reward.
Incorrect or slow responses are followed by a $1
loss. The ACR task provides only 25% money
wins and introduces reward violation (unexpected
non reward) in 25% of the trials, which results in
strongly engagement of the insula, ACC and also
putamen predominantly during reward outcomes.
4.4. Statistical Design and Power
Design and power-NEW-6.22.18.pdf
4.5. Subject Participation Duration
3 weeks
4.6. Will the study use an FDA-regulated intervention?
●
Yes
❍
No
4.6.a. If yes, describe the availability of Investigational
Product (IP) and Investigational New Drug (IND)/
Investigational Device Exemption (IDE) status
Availability of product.pdf
4.7. Dissemination Plan
Dissemination plan.pdf
Contact PD/PI: Newcorn, Jeffrey H
Page 87
Effective Date: 12/19/2023
End Date:12/18/2024


Brief summary
We propose to study the effects of 3 weeks of treatment with MAS-XR on the brain reward 
system in youth with ADHD only (LR) vs. ADHD + CD or severe ODD (HR). We will study 36 
treatment- and drug-naïve youth (18 per risk group) ages 7 – 12 years. LR and HR subjects will 
be assessed with clinical and neuropsychological measures and will be subjected to fMRI scans 
twice – before and after 3 weeks of treatment with mixed amphetamine salts- extended release 
(MAS-XR). The fMRI scans will be conducted while participants perform the Anticipation, 
Reward, Conflict (ACR) task developed by our group, which has a unique component of 
unexpected non-reward. Combining prediction error analyses with purported activation 
differences on this particular component of the ACR will offer a never before explored approach 
to assess differences between youth at different risk levels for SUD. Importantly, our event-
related design will distinguish increased effort and associated anticipatory activation (a positive 
effect) from increased hedonics of reward (a potentially deleterious effect).
Study design 
This is an open label trial which will recruit two groups of drug naïve youth ages 7-12. The Low 
Risk (LR) group will consist of children diagnosed with ADHD only and the High Risk (HR) group 
will consist of children diagnosed with ADHD and severe ODD or CD. Both groups will receive 
treatment with Mixed Amphetamine slats (MAS-XR) and will undergo two fMRI scans – the first 
scan will be performed before treatment and the second will be performed after 3 weeks of 
treatment. The main outcome measures will be the activation in brain regions indexed by the 
fMRI while the participants perform a reward task in the scanner
Study Periods The study will consist of 5 visits including screen, baseline and 3 treatment visits. 
Participants will be scanned at visit 2 and rescanned at visit 5. They will receive treatment with 
MAS-XR with flexible dosing. The main goal of the treatment is to index purported changes in 
the activation of the brain reward circuits as changes in BOLD signal will be our primary 
outcome. We will also assess for changes in ADHD symptoms and medication adjustments will 
be guided by changes in those symptoms. Therefore the objective of the study is to index 
changes in BOLD signal pre to post treatment with MAS-XR which is a first line medication for 
the treatment of ADHD and has known abuse potential
Study Period I: Screening/baseline (Visits 1–2). The 1st and 2nd visits both involve assessment; 
the 2nd visit also includes the baseline fMRI scan. Subjects will have a “mock scan” at the 1st 
visit, following established guidelines. We anticipate that the assessment procedures can be 
completed in 2 study visits within 14 days. The screening period can be lengthened to 
accommodate washout of a non-stimulant drug if this is required. 
Study Period II: 2 Week Treatment Block (Days 0 to 21). Subjects will receive open label 
treatment with MAS-XR for 3 weeks. Medication will be titrated using a fixed dose approach, 
with doses that mimic those used in clinical practice. The two assigned doses are 0.25 mg/kg 
and 0.5 mg/kg, with an option to increase to 1.0 mg/kg if needed. At study completion, 
participants will complete the post-treatment fMRI scan and all clinical measures. There will be 2 
visits during this period - one after 1 week of treatment and one at 3 weeks (EOT). There will be 
a phone visit at the end of the second treatment week, though subjects can be seen if 
necessary.  
Study medication and medication administration. Subject treated with non-stimulants will be 
required to be off medication for 2 weeks prior to scan. We will purchase MAS–XR, an extended 
release generic amphetamine formulation. Subjects will begin at 0.25 mg/kg and increase to 0.5 
Contact PD/PI: Newcorn, Jeffrey H
Statistical Design and Power
Page 88
Effective Date: 12/19/2023
End Date:12/18/2024


mg/kg after one week. This dose can be reached (within ~5 mg) using 2 capsules of 
commercially available doses. Those who cannot increase the dose due to AEs will be allowed 
to maintain their dose and be evaluated for a dose increase after 2 weeks. Subjects who 
experience difficulty with symptom control can titrate to a higher dose if need be (maximum 1 
mg/kg). Subjects who increase their dose and experience AEs will be allowed to lower their 
dose. Subjects will receive MAS–XR on the day of the second scan approximately 6-8hrs before 
scan. 
Data Analysis
First level (within-subject) analyses will be conducted for each participant with a general linear 
model (GLM) to quantify the relationship between the observed event-related BOLD signals and 
regressors encoding expected trial-specific responses. The design matrix will be comprised of 
12 regressors: 2 for cue (reward vs. non-reward) x 2 for target type (congruent or incongruent 
flankers) x 3 for outcome-related effects (reward, non-reward, punishment). There are 4 
outcome contrasts of interest: reward following reward cue, non-reward following reward cue, 
non-reward following non-reward cue, or punishment for an incorrect/missing response.
Group-level Statistical Analysis.  Descriptive statistics (e.g., means, standard deviations (SD), 
etc.) for all variables of interest will be computed and compared by Student t test for continuous 
variables or Chi-square test for categorical variables. Group statistical analyses of the imaging 
data will be performed using a GLM from SPM. The GLM is written as Y=XB+E, where Y is a 
matrix with a series of multivariate measurements, X is a design matrix, B is a matrix containing 
parameters that are usually to be estimated and E is a matrix containing errors or noise. The 
errors are usually assumed to follow a multivariate normal distribution 
Primary Aim. We will test two hypotheses: 1a) the HR group will show greater baseline 
activation than LR (during the ACR task) in the insula, putamen, and ACC); 1b) MAS-XR 
treatment will reduce the activation in the brain reward system for both groups, possibly in 
greater magnitude for HR. We will run F-tests of the voxel-based whole brain activation pattern 
with ANCOVA controlling for time (baseline, post-treatment) with two groups (HR, LR) with age, 
sex, IQ and medication dose level included as covariates. We will run independent t-test to 
compare activation at baseline and at and of treatment between HR vs. LR participants. The 
voxel-based Z statistic images will be thresholded using clusters determined by Z>2.3 and a 
cluster corrected significance threshold of p<0.05. 
Exploratory Aim.  We will conduct correlation analyses between pre to post- treatment 
measures of activation in the reward system and scores on the behavioral measures collected 
outside the scanner (i.e., Kirby, BIS/BAS, UPPS) to examine the direction and magnitude of 
correlations between brain function and behavior. 
Power analyses. The main power considerations for the primary aim are related to the ability to 
detect differences in activation between the two groups pre- to post treatment. We estimated 
power using Monte Carlo simulations (10,000 draws per model), with α = 0.05, for all models. 
With a between subjects factor (2-levels; LR, HR) and 4 covariates (age, sex, IQ, dose level), 
we were able to recover large effects sizes (f = .80-1.0) for the between group factor with 40 
ADHD subjects, which corresponds to approximately a .8-1 difference in activation. For the 
exploratory aim, we used regression models with the behavioral measures, the same 4 
covariates, using the baseline level of each behavioral measure to control for time effects and 
activation as the dependent variable.  In the simulations, we were able to recover effect sizes of 
d =.2-3 with 4-5 independent nuisance covariates (age, sex, IQ, does), and baseline covariates 
with a correlation of .35 in the model.  
Contact PD/PI: Newcorn, Jeffrey H
Statistical Design and Power
Page 89
Effective Date: 12/19/2023
End Date:12/18/2024


MAS –XR is FDA approved and is available through the investigational drug service. 
Contact PD/PI: Newcorn, Jeffrey H
Investigational Availability
Page 90
Effective Date: 12/19/2023
End Date:12/18/2024


Dissemination plan 
The Co-Principal Investigators are committed to the development of large, shared data bases 
which can be used to study the neurobiological basis of substance abuse risk. This is very much 
in line with the current efforts of NIDA to launch the Adolescent Brain Cognitive Development 
(ABCD) Study, which we feel the proposed research will complement and augment. We 
appreciate that the public dissemination of our scientific results will potentially facilitate the 
creation of collaborative efforts, with outside investigators playing an important role in helping to 
further understand the topics to be addressed in this research. Research data will be shared 
according to the most recent NIH guidelines (http://www.ott.nih.gov/policy/rt_guide_final.html). 
We are mindful that the rights and privacy of people who participate in research must be 
protected at all times, that there is the need to protect patentable and other proprietary data, 
and that restrictions on data sharing may be imposed by agreements with third parties. In this 
regard, Icahn School of Medicine at Mount Sinai is and will remain HIPAA compliant, and 
therefore any datasets resulting from human participant research will be free of any identifiers 
that would permit linkages to individual research participants and variables that could lead to 
deductive disclosure of individual subjects. 
Timelines for distribution of data will vary depending on the nature of the data to be shared and 
any required restrictions. In addition to communication channels such as speaking 
engagements and publications, data may be distributed by a number of electronic methods, 
including web-based databases, datasets, and spreadsheets, or via electronic media such as 
CDs, DVDs, and tape. The method(s) of distribution employed will be determined at a later date.
Contact PD/PI: Newcorn, Jeffrey H
Dissemination Plan
Page 91
Effective Date: 12/19/2023
End Date:12/18/2024


Tracking Number: GRANT12677775
Funding Opportunity Number: PA-18-344 Received Date:
2018-07-16T12:51:37.000-04:00
Delayed Onset Studies
Delayed
Onset
Study#
Study Title
Anticipated Clinical
Trial?
Justification
The form does not have any delayed onset studies
Contact PD/PI: Newcorn, Jeffrey H
Page 92
Effective Date: 12/19/2023
End Date:12/18/2024


Roles/Areas of responsibility of the Principal Investigators (PIs)
As joint PIs, Drs. Jeffrey Newcorn and Iliyan Ivanov will be jointly responsible for the scientific 
direction and productivity of the research study. The multiple PI structure reflects the unique 
expertise each brings to this project, their successful history of joint leadership, and the joint 
collaboration on this project. Dr. Newcorn is a board certified child and adolescent psychiatrist 
and developmental cognitive neuroscientist with vast experience in childhood psychopathology 
and pharmacological treatment of neurodevelopmental disorders in childhood and adolescence. 
He has an extensive history of NIH funding and scientific research in the area of neuroimaging 
(functional and structural MRI and DTI) as well as longitudinal studies of children with ADHD; he 
is currently PI of a R01 grant investigating brain activation and connectivity differences 
associated with stimulant and non-stimulant pharmacological treatments for ADHD. He is 
experienced with administrative duties related to large-scale clinical research projects. Dr. 
Ivanov is a board certified child and adolescent psychiatrist and developmental cognitive 
neuroscientist who has completed a NIDA K-12 Award for which Dr. Newcorn was the primary 
mentors. He has extensive clinical experience in the assessment and treatment of adolescent 
SUD and is an expert in implementing neuroimaging techniques for the study of biological 
markers of clinical risks for later SUD. Both PIs will have joint decision-making authority with 
respect to administration. The scientific aims of this project are best served by the combination 
of these areas of expertise.
Fiscal and management coordination:
The PIs will jointly provide oversight of the entire proposed project and development and 
implementation of all policies, procedures, and processes. As such, both PIs will be responsible 
for the implementation of the research plan, achievement of the specific aims, and institutional 
compliance regarding human subjects. They will be jointly responsible for fiscal and research 
administration, including human subjects approval, participant characterization and will jointly 
oversee MRI data collection and analysis. Given his significant administrative experience, Dr. 
Newcorn will serve as contact PI and be responsible for all communication with NIH, including 
submission of progress reports.
Process for making decisions on scientific direction and allocation of resources:
The PIs will hold weekly meetings to discuss experimental design, data analysis, and all 
administrative responsibilities. They have published several papers together. They keep in daily 
contact via email and phone.  Given their long standing collaboration history they will work 
closely together with equal decision-making power to consider and discuss any changes in the 
direction of the research projects, including the reallocation of funds, if necessary.
Data sharing and communication among investigators:
Both PIs will share their respective raw, de-identified data and research results with each other 
and key personnel. This data sharing will be facilitated through the existing data 
coordination/sharing processes in place for all current collaborations between the PIs.
Publication and intellectual property (if needed) policies:
Publication authorship will be based upon the relative scientific contributions of the PIs and key 
personnel, consistent with current Sinai and NIH policies. 
Procedures for resolving conflicts:
If a potential conflict develops, the PIs shall meet and attempt to resolve the dispute. If they fail 
to resolve the dispute, the disagreement will be referred to a multiple PI arbitration committee 
composed of faculty of ISMMS. Any Chairs, Institute Directors or Division Chiefs on the 
committee must recuse themselves if any of the PIs have appointments in their department, 
Contact PD/PI: Newcorn, Jeffrey H
Multiple PD/PI Leadership Plan
Page 93
Effective Date: 12/19/2023
End Date:12/18/2024


institute, or division, respectively. The committee will be co- chaired by the Dean for Research 
Operations and Infrastructure and the Dean for Translational Biomedical Research. All PIs 
agree that any decisions made will be final and binding.
Change in PI Location. 
If a PI moves to a new institution, attempts will be made to transfer the relevant portion of the 
grant to the new institution. In the event that a PI cannot carry out his or her duties, a new PI will 
be recruited as a replacement at one of the participating institutions by the remaining PI and the 
PI that is relocating.
Contact PD/PI: Newcorn, Jeffrey H
Multiple PD/PI Leadership Plan
Page 94
Effective Date: 12/19/2023
End Date:12/18/2024


REFERENCES
1 – Flory K & Lynam DR. The relation between attention deficit hyperactivity disorder and substance abuse: 
what role does conduct disorder play? Clin Child Fam Psychol Rev. 2003 Mar;6(1):1-16.
2 - Newcorn JH et al., Atomoxetine/Methylphenidate Comparative Study Group. Atomoxetine and osmotically 
released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and 
differential response. Am J Psychiatry. 2008 Jun;165(6):721-30.
3 - Robinson TE, Berridge KC. (2000) The psychology and neurobiology of addiction: an incentive-sensitization 
view, Addiction, 95(suppl. 2), S91– S118
4 - Marco EM et al., Neurobehavioral adaptations to methylphenidate: the issue of early adolescent exposure. 
Neurosci Biobehav Rev. 2011 Aug; 35(8):1722-39.
5 – Wooters TE, et al., Methylphenidate enhances the abuse-related behavioral effects of nicotine in rats: 
intravenous self-administration, drug discrimination, and locomotor cross-sensitization. . 
Neuropsychopharmacology. 2008 Apr; 33(5):1137-48, 
6 - Jordan CJ, et al., Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder 
following adolescent methylphenidate or atomoxetine treatments. . Drug Alcohol Depend. 2014 Jul 1;140:25-
32.
7 - Humphreys KL, Eng T, and  Lee S. Stimulant medication and substance use outcomes: a meta-analysis. 
JAMA Psychiatry. ,2013.Jul;70(7):740-9. 
8 - Blair RJ, Leibenluft E, and Pine D. Conduct disorder and callous-unemotional traits in youth. N Engl J 
Med.19;372(8):784, 2015.
9 - Grant JE & Chamberlain, S. Impulsive action and impulsive choice across substance and behavioral 
addictions: cause or consequence? Addict Behav. 39(11):1632-9, 2014.
10 - Bjork J &  Pardini M. Who are those "risk-taking adolescents"? Individual differences in developmental 
neuroimaging research. Dev Cogn Neurosci. Dev Cogn Neurosci.11:56-64, 2015.
11 – Motzkin JC et al., Neural correlates of substance abuse: reduced functional connectivity between areas 
underlying reward and cognitive control. Hum Brain Mapp. 2014 Sep; 35(9):4282-92.
12 – Scervenka A et al., Resting state functional connectivity of the nucleus accumbens in youth with a family 
history of alcoholism.  Psychiatry Res. 2014 Mar 30; 221(3): 210–219. 
13 - Kohna M et al., Risky decision making, prefrontal cortex, and mesocorticolimbic functional connectivity in 
methamphetamine dependence. JAMA Psychiatry. 2014 Jul 1;71(7):812-20.
14 - Hasler BP et al. An altered neural response to reward may contribute to alcohol problems among late 
adolescents with an evening chronotype. Psychiatry Res. 2013Dec 30;214(3):357-64.
15 - Yip SW et al., Pretreatment measures of brain structure and reward-processing brain function in cannabis 
dependence: an exploratory study of relationships with abstinence during behavioral treatment. Drug Alcohol 
Depend. Jul 1;140:33-41, 2014.
16 - Rubia K, et al., Methylphenidate normalises activation and functional connectivity deficits in attention and 
motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task. 
Neuropharmacology. 2009 Dec;57(7-8):640-52.
Contact PD/PI: Newcorn, Jeffrey H
References Cited
Page 95
Effective Date: 12/19/2023
End Date:12/18/2024


17 – Mizuno K, et al., Osmotic release oral system-methylphenidate improves neural activity during low reward 
processing in children and adolescents with attention-deficit/hyperactivity disorder. Neuroimage Clin. Mar 
2013; 16;2:366-76.
18 - Ivanov I, et al., Parental substance abuse and function of the motivation and behavioral inhibition systems 
in drug-naïve youth. Psychiatry Res. 2012 Feb 28;201(2):128-35.
19 – Plichta MM and Scheres A. Ventral-striatal responsiveness during reward anticipation in ADHD and its 
relation to trait impulsivity in the healthy population: a meta-analytic review of the fMRI literature. . Neurosci 
Biobehav Rev. 2014; 38:125-34.
20 - von Rhein D, et al. Increased neural responses to reward in adolescents and young adults with attention-
deficit/hyperactivity disorder and their unaffected siblings. J Am Acad Child Adolesc Psychiatry. 2015; 
54(5):394-402.
21 - Knutson B., Taylor J., Kaufman M., Peterson R., Glover G. Distributed neural representation of expected 
value. Journal of Neuroscience. 2005;25:4806–4812.
22 - Liu X., Powell D.K., Wang H., Gold B.T., Corbly C.R., Joseph J.E. Functional dissociation in frontal and 
striatal areas for processing of positive and negative reward information. Journal of 
Neuroscience. 2007;27:4587–4597.
23 - Breiter H.C., Aharon I., Kahneman D., Dale A., Shizgal P. Functional imaging of neural responses to 
expectancy and experience of monetary gains and losses. Neuron. 2001;30:619–639.
24 -Izuma K., Saito D.N., Sadato N. Processing of social and monetary rewards in the human 
striatum. Neuron. 2008;58:284–294.
25 - Knutson B., Fong G.W., Bennett S.M., Adams C.M., Hommer D. A region of mesial prefrontal cortex tracks 
monetarily rewarding outcomes: characterization with rapid event-related fMRI. NeuroImage. 2003;18:263–
272.
26 - Nieuwenhuis S., Slagter H.A., von Geusau N.J., Heslenfeld D.J., Holroyd C.B. Knowing good from bad: 
differential activation of human cortical areas by positive and negative outcomes. European Journal of 
Neuroscience. 2005;21:3161–3168.
27 - Dillon D.G., Holmes A.J., Jahn A.L., Bogdan R., Wald L.L., Pizzagalli D.A. Dissociation of neural regions 
associated with anticipatory versus consummatory phases of incentive 
processing. Psychophysiology. 2008;45:36–49.
28 - O'Doherty J., Winston J., Critchley H., Perrett D., Burt D.M., Dolan R.J. Beauty in a smile: the role of 
medial orbitofrontal cortex in facial attractiveness. Neuropsychologia. 2003;41:147–155.
29 - Goldstein R & Volkow N. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and 
clinical implications. Nature Reviews Neuroscience 2011, Nov 12, 652-669. 
30 - Calipari ES, Jones SR. Sensitized nucleus accumbens dopamine terminal responses to methylphenidate 
and dopamine transporter releasers after intermittent-access self-administration. Neuropharmacology. 2014 
Jul;82:1-10.
31- Robinson T. E. & Becker, J. B. (1982) Behavioral sensitization is accompanied by an enhancement in 
amphetamine-stimulated dopamine release from striatal tissue in vitro, European Journal of Pharmacology, 85, 
253–254.
32- Robinson T. E. & Berridge, K. C. (1993) The neural basis of drug craving: an incentive-sensitization theory 
of addiction, Brain Research Reviews, 18, 247– 291.
Contact PD/PI: Newcorn, Jeffrey H
References Cited                                                                                              
Page 96
Effective Date: 12/19/2023
End Date:12/18/2024


33 -Kalivas, P. W. & Steward, J. (1991) Dopamine trans- mission in the initiation and expression of drug- and 
stress-induced sensitization of motor activity, Brain Research Reviews, 16, 223–244.
34 - Nestby, P., Vanderschuren , L. J. & De Vries, T. J. (1997) Ethanol, like psychostimulants and mor- phine, 
causes long-lasting hyperreactivity of dopamine and acetylcholine neurons of rat nucleus accumbens: possible 
role in behavioural sensitization, Psychopharmacology, 133, 69–76.
35 - Pierce, R. C. & Kalivas, P. W. (1997) A circuitry model of the expression of behavioral sensitization to 
amphetamine-like psychostimulants, Brain Research Reviews, 25, 192–216.
36 - Kantor, L., Hewlett, G. H. & Gnegy, M. E. (1999) Enhanced amphetamine- and K 1 -mediated dopamine 
release in rat striatum after repeated am- phetamine: differential requirements for Ca2 1 - and calmodulin-
dependent phosphorylation and synaptic vesicles, Journal of Neuroscience, 19, 3801–3808. 
37 -Vanderschuren , L. J.,Warden, G., De Vries, T. J. Mulder, A. H. & Schoffelmeer , A. N. (1999a) 114 Terry 
E. Robinson & Kent C. Berridge Opposing role of dopamine D1 and D2 receptors in modulation of rat nucleus
accumbens noradrenaline release, Journal of Neuroscience, 19, 4123–4131.
38 – White F. J. & Kalivas, P. W. (1998) Neuroadaptations involved in amphetamine and cocaine addiction, 
Drug and Alcohol Dependence, 51, 141–153. 
39 - Henry D. J. & White, F. J. (1991) Repeated cocaine administration causes persistent enhancement of D1 
dopamine receptor sensitivity within the rat nucleus accumbens, Journal of Pharmacology and Experimental 
Therapeutics, 258, 882–890. 
40 - Ansquer S et al., Atomoxetine decreases vulnerability to develop compulsivity in high impulsive rats. Biol 
Psychiatry. 2014 May 15;75(10):825-32.
41- Dalsgaard S, et al., ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood
- a naturalistic long-term follow-up study. Addict Behav. 2014 Jan;39(1):325-8.
42- Torgersen T et al., Prevalence of comorbid substance use disorder during long-term central stimulant
treatment in adult ADHD. Atten Defic Hyperact Disord. 2013 Mar; 5(1):59-67.
43 - Marquand A et al., Pattern Classification of Working Memory Networks Reveals Differential Effects of 
Methylphenidate, Atomoxetine, and Placebo in Healthy Volunteers. Neuropsychopharmacology. 2011 May; 
36(6): 1237–1247.
44 – Biederman J et al., Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance 
use disorder. Pediatrics. 1999;104(2):e20. 
45 - Loney J, Kramer JR, and Salisbury H. Medicated vs. unmedicated ADHD children: Adult involvement with 
legal and illegal drugs. In: Jensen PS, Cooper JR, editors. Attention Deficit Hyperactivity Disorder. State of the 
Science Best Practices. Kingston, NJ: Civic Research Institute; 2002. 
46 - Mannuzza S et al. Age of methylphenidate treatment initiation in children with ADHD and later substance 
abuse: Prospective follow-up into adulthood. Am J Psychiatry. 2008;165:604–609.
47 - Lambert NM, McLeod M, and Schenk S. Subjective responses to initial experience with cocaine: an 
exploration of the incentive-sensitization theory of drug abuse. Addiction. 2006 May; 101(5):713-25.
48 - Lambert NM. The contribution of childhood ADHD, conduct problems, and stimulant treatment to 
adolescent and adult tobacco and psychoactive substance abuse. Ethical Human Psychol Psychiatry. 
2005;7(3):197–221
49 - Lambert NM, Hartsough CS Prospective study of tobacco smoking and substance dependencies among 
samples of ADHD and non-ADHD participants. J Learn Disabil. 1998 Nov-Dec; 31(6):533-44.
Contact PD/PI: Newcorn, Jeffrey H
References Cited
Page 97
Effective Date: 12/19/2023
End Date:12/18/2024


50 - Biederman J et al., Stimulant therapy and risk for subsequent substance use disorders in male adults with 
ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry. 2008 May; 165(5):597-603.
51 - Barkley RA  et al., Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute 
to drug use/abuse? A 13-year prospective study. Pediatrics. 2003 Jan; 111(1):97-109.
52 - Harty SC, et al. The impact of conduct disorder and stimulant medication on later substance use in an 
ethnically diverse sample of individuals with attention-deficit/hyperactivity disorder in childhood. J Child 
Adolesc Psychopharmacol. Aug;21(4):331-9. 2012.
53 - Substance Abuse and Mental Health Services Administration. Rockville, MD: Office of Applied Studies; 
2009. Results from the 2008 National Survey on Drug Use and Health: National Findings. NSDUH Series H-
36, HHS Publication No. (SMA) 09-4434.
54 - Molina BS, et al. Adolescent substance use in the multimodal treatment study of attention-
deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood 
treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry. 52(3):250-63, 2013.
55 - LeDoux JE &, Pine DS. Using Neuroscience to Help Understand Fear and Anxiety: A Two-System 
Framework. Am J Psychiatry. 2016;173(11):1083-1093. 
56 - Whitfield-Gabrieli S et al., Brain connectomics predict response to treatment in social anxiety disorder. Mol 
Psychiatry 2016; 21:680–685.
57 - Doehrmann O et al,. Predicting treatment response in social anxiety disorder from functional magnetic 
resonance imaging. JAMA Psychiatry 2013; 70:87–97.
 
58 - Carmona S, et al. Response inhibition and reward anticipation in medication-naïve adults with attention 
deficit/hyperactivity disorder: a within-subject case-control neuroimaging study. Hum Brain Mapp. 
Oct;33(10):2350-61, 2012.
59 - De Sanctis VA, et al., Childhood maltreatment and conduct disorder: independent predictors of
adolescent substance use disorders in youth with attention deficit/hyperactivity disorder. J Clin Child 
Adolesc Psychol. 2008 Oct;37(4):785-93 
60 - Rebec GV. Cocaine and Amphetamines. Published Online: 15 AUG 2012
DOI: 10.1002/9780470015902.a0000042.pub3
61 - Kuczenski R1, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and 
norepinephrine: comparison with amphetamine. J Neurochem. 1997 May;68(5):2032-7.
62 – Mariani JJ, Levi FR. Psychostimulant Treatment of Cocaine Dependence Psychiatr Clin North Am. 2012 
Jun; 35(2): 425–439. 
63 - Ivanov I, et al. Methylphenidate and brain activity in a reward/conflict paradigm: role of the insula in task 
performance. Eur Neuropsychopharmacol. Jun;24(6):897-906., 2014.
Contact PD/PI: Newcorn, Jeffrey H
References Cited                                                                                              
Page 98
Effective Date: 12/19/2023
End Date:12/18/2024


64 - Swanson J,  Baler RD, Volkow ND. Understanding the Effects of Stimulant Medications on Cognition in 
Individuals with Attention-Deficit Hyperactivity Disorder: A Decade of Progress Neuropsychopharmacology. 
2011 Jan; 36(1): 207–226.
65 - Spencer TS, Brown A,  Seidman LJ, Valera EM, Makris N  Lomedico A,  Faraone SV,  Biederman J. 
Effect of Psychostimulants on Brain Structure and Function in ADHD: A Qualitative Literature Review of MRI-
Based Neuroimaging Studies J Clin Psychiatry. 2013 Sep; 74(9): 902–917.
66 -  Yang Z, Kelly C, PhD,. Castellanos FX, Leon T, MS,  Milham M, Adler LA. Neural Correlates of 
Symptom Improvement Following Stimulant Treatment in Adults with Attention-Deficit/Hyperactivity Disorder J 
Child Adolesc Psychopharmacol. 2016 Aug 1; 26(6): 527–536.  
67 - Galvan A. Adolescent development of the reward system. Front Hum Neurosci, 2010. 4: p. 6.
68 - Schulz KP, et al., Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments 
for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 69(9):952-6, 2012.
69 - Schwab-Stone ME, et al. Criterion validity of the NIMH Diagnostic Interview Schedule for Children Version 
2.3 (DISC-2.3). Journal of the American Academy of Child and Adolescent Psychiatry, 35(7):  878-888, 1996.
70 -  Makransky G, Bilenberg N. Psychometric properties of the parent and teacher ADHD Rating Scale 
(ADHD-RS): measurement invariance across gender, age, and informant.Assessment. 21(6):694-705, 2014.
71 - Swanson J, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of 
ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry; 40(2):168-79,  2001.
72 - Wechsler D. Wechsler Abbreviated Scale of Intelligence (WASI). San Antonio, TX: Harcourt    
Assessment, Inc.1999.
73 - Barkley R., et al. Side Effects of MPH in Children with Attention Deficit Hyperactivity Disorder: A      
Systematic Placebo Controlled Evaluation. Pediatrics, 186(184-192), 1990.
74 - Achenbach T and Edelbrock C. Manual for the CBCL and 1991 profile. Burlington, VT: University of 
Vermont, 1991.
75 - NIMH, Clinical Global Impressions. Psychopharmacology Bulletin, 21: 839-843, 1985.
76 - Pausova Z, Genes, maternal smoking, and the offspring brain and body during adolescence: design of 
the Saguenay Youth Study. Hum Brain Mapp. 28(6):502-18, 2007.
77 – Collaborqtive Study on the Genetics of Alcoholism, Washington Univ St Luis.  
https://niaaagenetics.org/coga_instruments/phaseI/fham/fham.htm
78 - Glover V, et al. Avon Longitudinal Study of Parents and Children (ALSPAC) Protocol Edinburgh 
Handedness Inventory Scoring Method. Early Human Development, (79): 107-118, 2004.
79 - Marshall W and Tanner J. Variations in the pattern of pubertal changes in boys. Archives of Disease in 
Childhood, 45:13-23, 1970.      
80 - Posner K, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency 
findings from three multisite studies with adolescents and adults. Am J Psychiatry,168(12):1266-77, 2011.
81 - Carver CS and White TL. Behavioral inhibition, behavioral activation, and affective responses to 
impending reward and punishment: the BIS/BAS scales. Journal of personality and social psychology, 67(2): 
319, 1994.
82 - Costumero V, et al. BAS-drive trait modulates dorsomedial striatum activity during reward response-
outcome associations. Brain Imaging Behav. 2015.
Contact PD/PI: Newcorn, Jeffrey H
References Cited
Page 99
Effective Date: 12/19/2023
End Date:12/18/2024


83 - Kirby KN. One-year temporal stability of delay-discount rates Psychonomic bulletin & review, 16,
457–462, 2009.
84 - Benningfield M, et al. Caudate responses to reward anticipation associated with delay discounting    
behavior in healthy youth Developmental Cognitive Neurosceince, 7; 43–52, 2014.
85 - Whiteside SP, Lynam DR. Understanding the role of impulsivity and externalizing psychopathology in 
alcohol abuse: application of the UPPS impulsive behavior scale. Exp Clin Psychopharmacol. 2003 
Aug;11(3):210-7.
86 - Li YO, Adali T, and Calhoun V. Estimating the number of independent components for functional magnetic 
resonance imaging data. Hum. Brain Mapp. 28: 1251-1266, 2007.
87 - Green G and Diggle P. On the operational characteristics of the Benjamini and Hochberg False Discovery 
Rate procedure. Stat. Appl. Genet. Mol. Biol. 6: Article27, 2007.
88 - DeWit DJ, Offord DR, and Wong, M. Patterns of onset and cessation of drug use over the early part of the 
life course. Health Educ Behav. 24(6): 746-58, 1997.
89 - Nagel L, McDougall D, and Granby C. Students' self-reported substance use by grade level and gender. 
Drug Educ. 26(1): 49-56,1996.
90 -  Rangaswamy M, et al.  A functional MRI study of visual oddball: evidence for frontoparietal dysfunction in 
subjects at risk for alcoholism. Neuroimage 21(1): 329-39., 2004.
91 - Schweinsburg AD, et al. An FMRI study of response inhibition in youths with a family history of alcoholism.  
Ann N Y Acad Sci. 1021: 391-4, 2004.
92 - Halperin JM, et al. Familial correlates of central serotonergic function in children with disruptive behavior 
disorders. Psychiary Research, 119, 205-216, 2003.
93 - Abikoff H, et al. Emergency/Adjunct services and attrition prevention for randomized clinical trials in 
children: the MTA manual-based solution. Journal of the American Academy of Child and Adolescent 
Psychiatry, 41:  498-504. 2002.
Contact PD/PI: Newcorn, Jeffrey H
References Cited                                                                                              
Page 100
Effective Date: 12/19/2023
End Date:12/18/2024

ICF_001.pdf: 
Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for 
Substance Use Disorder
PI: Jeffrey Newcorn
NCT04170738
Document Date: 11-8-2022


THE MOUNT SINAI HEALTH SYSTEM 
PERMISSION FORM FOR A CHILD TO PARTICIPATE IN A RESEARCH STUDY
AND AUTHORIZATION FOR USE AND DISCLOSURE OF MEDICAL INFORMATION
Icahn School of Medicine at Mount Sinai
Page 1 of 15
Study ID #: GCO 17-1321
           Form Version Date: 4/1/2022
*Throughout this document “child” refers to a minor under applicable state law and “you” refers to any individual 
who may legally act on the minor’s behalf (e.g. parent or legal guardian)
---------------------------------------------------------FOR IRB USE ONLY--------------------------------------------------------------
Rev 6.22.16
TITLE OF RESEARCH STUDY:
Title: Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder
PRINCIPAL INVESTIGATOR (HEAD RESEARCHER) NAME AND CONTACT INFORMATION:
Name: Jeffrey Newcorn, MD and Iliyan Ivanov, MD
Physical Address: 19 East 98th Street, room 5E, NY, NY 10029
                           For fMRI scanning, the 1470 Madison Ave entrance will be used
Mailing Address: 1 Gustave L Levy Place Box 1230, NY, NY 10029
Phone: 212-659-8775 (Dr. Newcorn)
           646-535-1618 (Dr. Krone)
WHAT IS A RESEARCH STUDY?
A research study is when scientists try to answer a question about something that we don’t know 
enough about.  Participating may not help you or others.  
People volunteer to be in a research study.  The decision about whether or not to take part is totally 
up to you. You can also agree to give permission for your child to take part now and later change your 
mind. Whatever you decide is okay.  It will not affect your ability, or your child’s ability, to get medical 
care within the Mount Sinai Health System.  
Someone will explain this research study to you. Feel free to ask all the questions you want before 
you decide.  Any new information that develops during this research study which might make you 
change your mind about your child’s participating will be given to you promptly.
Basic information about this study will appear on the website http://www.ClinicalTrials.gov.  There are 
a few reasons for this:  the National Institutes of Health (NIH) encourages all researchers to post their 
research; some medical journals only accept articles if the research was posted on the website; and, 
for research studies the U.S. Food and Drug Administration (FDA) calls "applicable clinical trials” a 
description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. 
Law. This Web site will not include information that can identify you. At most, the Web site will include 
a summary of the results. You can search this Web site at any time.
Effective Date: 11/8/2022
End Date:11/7/2023


THE MOUNT SINAI HEALTH SYSTEM 
PERMISSION FORM FOR A CHILD TO PARTICIPATE IN A RESEARCH STUDY
AND AUTHORIZATION FOR USE AND DISCLOSURE OF MEDICAL INFORMATION
Icahn School of Medicine at Mount Sinai
Page 2 of 15
Study ID #: GCO 17-1321
           Form Version Date: 4/1/2022
*Throughout this document “child” refers to a minor under applicable state law and “you” refers to any individual 
who may legally act on the minor’s behalf (e.g. parent or legal guardian)
---------------------------------------------------------FOR IRB USE ONLY--------------------------------------------------------------
Rev 6.22.16
PURPOSE OF THIS RESEARCH STUDY:
The purpose of this study is to examine the way Adderall influences brain functioning and learning 
Your child may qualify to take part in this research study because he or she has ADHD and is willing 
to try Adderall, and play videogames in an fMRI scanner.  
Funds for conducting this research are provided by the National Institute for Drug and Alcohol Abuse.  
LENGTH OF TIME AND NUMBER OF PEOPLE EXPECTED TO PARTICIPATE
Your child’s participation in this research study is expected to last about a month. 
The number of people expected to take part in this research study at Mount Sinai is 48. 
DESCRIPTION OF WHAT’S INVOLVED:
If you agree to permit your child’s participation in this research study, the following information 
describes what may be involved. 
Many consent, screening, and follow-up procedures may be done via telehealth, meaning that a study 
team member may schedule you for a video-call and will speak to you while you and your child 
answer questions. If you are completing these procedures by telehealth, you will receive a link by 
email, and you can log in to sign consent and complete surveys on your computer, tablet, or cell 
phone.
The fMRI scan training (called Mock scanning) and the fMRI must take place face-to-face. For those 
procedures, you will arrive at the clinical entrance at the Hess building, at 1470 Madison Ave, before 
meeting a study doctor or coordinator in the lobby. At the clinical entrance, you and your child will be 
screened by hospital staff to make sure that you and your child are healthy enough to be allowed into 
the hospital’s scanning area. At this time, that means you will be checked for fever, and asked 
questions about your health. Also, at this time, only one parent and no siblings are allowed to enter 
the hospital with your child. If you and your child are not wearing a face mask, you will be given a 
mask that you must wear for your entire visit. You and your child need to wear the mask over your 
nose and mouth at all times while in the hospital and when in the study offices. If you or your child are 
feeling unwell, have a cough, fever, or other symptoms of illness, you will not be allowed into the 
hospital and your appointment will be rescheduled. The study team will direct you to the patient 
elevator, and will meet you downstairs in the scanning suite.
Effective Date: 11/8/2022
End Date:11/7/2023


THE MOUNT SINAI HEALTH SYSTEM 
PERMISSION FORM FOR A CHILD TO PARTICIPATE IN A RESEARCH STUDY
AND AUTHORIZATION FOR USE AND DISCLOSURE OF MEDICAL INFORMATION
Icahn School of Medicine at Mount Sinai
Page 3 of 15
Study ID #: GCO 17-1321
           Form Version Date: 4/1/2022
*Throughout this document “child” refers to a minor under applicable state law and “you” refers to any individual 
who may legally act on the minor’s behalf (e.g. parent or legal guardian)
---------------------------------------------------------FOR IRB USE ONLY--------------------------------------------------------------
Rev 6.22.16

SCREENING VISIT and BASELINE PROCEDURES: 
Before any study procedures are done, we will discuss the study and, if you choose to have your 
family participate, you will sign the consent forms. We will video record the consent process. After 
signing consent, your family will complete a screening visit interview and questionnaires. We will 
NOT video record the screening interviews or questionnaires. 
Screening procedures are usually completed over two separate days. 
Screening over telehealth video call includes:
o
Interviews, and you will complete forms discussing your child’s symptoms, medical 
history, and other information necessary to confirm a diagnosis
o
Your child will complete IQ testing and perform some other tasks that tell us about how 
he or she processes information, thinks, and responds to information. 
Screening face-to-face includes:
o
A physical exam and tests to make sure that he or she is healthy enough to participate 
in a trial of Adderall
o
Your child will try out a mock fMRI machine to become familiar with the machine, and 
to make sure that he or she can complete a scan
o
Finally, your child will complete an actual fMRI while playing a game in the scanner. 
The mock scan and the fMRI scan may happen on separate days.

TREATMENT VISIT PROCEDURES (may be done by telehealth):
Baseline to Week 1) After the fMRI, if your child is eligible to participate, he or she will be 
assigned to a low dose of Adderall. Your child will take the medication for a week and then, at 
the end of the week, our doctors will ask you:
o
questions about your child’s symptoms and side effects
o
Your child’s weight
o
to count the number of pills your child has taken during the week
The doctor may adjust your child’s medication dose, if necessary; and you will be told how 
to adjust the medication you give to your child.
Effective Date: 11/8/2022
End Date:11/7/2023


THE MOUNT SINAI HEALTH SYSTEM 
PERMISSION FORM FOR A CHILD TO PARTICIPATE IN A RESEARCH STUDY
AND AUTHORIZATION FOR USE AND DISCLOSURE OF MEDICAL INFORMATION
Icahn School of Medicine at Mount Sinai
Page 4 of 15
Study ID #: GCO 17-1321
           Form Version Date: 4/1/2022
*Throughout this document “child” refers to a minor under applicable state law and “you” refers to any individual 
who may legally act on the minor’s behalf (e.g. parent or legal guardian)
---------------------------------------------------------FOR IRB USE ONLY--------------------------------------------------------------
Rev 6.22.16
Week 1 to Week 2) Our doctors will ask you the same questions and complete the same 
procedures that you completed the week before. If medication changes need to be made, the 
doctor will discuss them with you. Your child will continue to take medication as directed. 
Week 2 to Week 3) 
Your child will take the medication for a week and then will return to the offices to see our 
doctors at the end of this week. By then, your child will have been on medication for three (3) 
weeks, and will be ending the study with another fMRI scan. 

END OF TREATMENT fMRI VISIT 
Before you come into the office for the final visit, you will complete some of the study 
procedures over telehealth video call, and by filling out forms online. 
o
We will ask you questions about symptoms and side effects
o
We will count the number of pills your child has taken during the week
o
You and your child will be asked to complete interviews and answer questions from 
scales that you had completed during the screening
o
You will be asked questions about your health and your child’s health to make sure you 
are healthy enough to come into the hospital.
When you arrive at the Hess building, at 1470 Madison Ave, you will pass through the clinical 
entry point just like you were at your visit for the first scan and training. 
o
Your child will have blood pressure and weight checked
o
Your child will complete an actual fMRI while playing a game in the scanner and 
perform some other tasks that tell us about how he or she processes information, 
thinks, and responds to information.
o
This is the end of the study
After the end of the study, your study team will discuss your plans for continuing care and help 
you with referrals to treatment. 
Optional Sharing of Information. 
Your child may be eligible for participation in more than one study conducted by the researchers in 
our program. The researchers in our program often use the same assessments across studies. 
This means that you and your child will only need to perform some assessments once, but you 
can participate in more than one study at the same time. Each study that asks for identifying 
information will still ask for your consent to participate before we will release the information. 
Effective Date: 11/8/2022
End Date:11/7/2023


THE MOUNT SINAI HEALTH SYSTEM 
PERMISSION FORM FOR A CHILD TO PARTICIPATE IN A RESEARCH STUDY
AND AUTHORIZATION FOR USE AND DISCLOSURE OF MEDICAL INFORMATION
Icahn School of Medicine at Mount Sinai
Page 5 of 15
Study ID #: GCO 17-1321
           Form Version Date: 4/1/2022
*Throughout this document “child” refers to a minor under applicable state law and “you” refers to any individual 
who may legally act on the minor’s behalf (e.g. parent or legal guardian)
---------------------------------------------------------FOR IRB USE ONLY--------------------------------------------------------------
Rev 6.22.16
(1) Will you allow the researchers to transfer your child’s information to use in other research 
studies in which you want to participate?
Yes________ No_________ 
The researchers would like to ask your permission to keep the data collected from your child 
during this study to use them in future research studies. Please tell us how we may use this 
material in future research studies. 
(1) Will you allow the researchers to store your child’s information to use in future research 
studies?
Yes________ No_________ If no, please stop here. If yes, please continue to the
next question.
(2) The researchers can keep your child’s information stored in one of two different ways: one way 
will store your child’s information in a way that it is linked to his/her identity (through the use of a 
code that can indicate the information came from him/her personally) and the other way will store 
your child’s information anonymously (no one will know who the information is from). It will not be 
stored both ways, so you must choose one of these two options. Please note that if you choose to 
have your child’s information stored anonymously, you will not be able to change your mind to ask 
for your child’s information to be destroyed at a future date. How would you like your child’s 
information stored? Please initial ONE choice:
I would like my child’s information stored with a link to my identity___________
I would like my child’s information stored anonymously _____________
Do you give permission to have assessment information (including the screening and outcome 
measures) given to other researchers at Mount Sinai or other institutions for use in research that 
is either related or not related to the purpose of this study?  Please initial your choice:
Yes_________ No__________
Effective Date: 11/8/2022
End Date:11/7/2023


THE MOUNT SINAI HEALTH SYSTEM 
PERMISSION FORM FOR A CHILD TO PARTICIPATE IN A RESEARCH STUDY
AND AUTHORIZATION FOR USE AND DISCLOSURE OF MEDICAL INFORMATION
Icahn School of Medicine at Mount Sinai
Page 6 of 15
Study ID #: GCO 17-1321
           Form Version Date: 4/1/2022
*Throughout this document “child” refers to a minor under applicable state law and “you” refers to any individual 
who may legally act on the minor’s behalf (e.g. parent or legal guardian)
---------------------------------------------------------FOR IRB USE ONLY--------------------------------------------------------------
Rev 6.22.16
RESPONSIBILITIES FOR PARTICIPATING IN THIS RESEARCH:
If you decide to permit your child to take part in this research study, you would be responsible for the 
following things: supervising your child’s use of the medication, providing accurate information about 
your child’s response to the medication, and attending appointments as scheduled. 
COSTS OR PAYMENTS THAT MAY RESULT FROM PARTICIPATION:
Taking part in this research study may lead to added costs for your child, such as travel expenses, or 
for time off of work
If you agree to permit your child to take part in this research study, we will pay your family $50 for 
each of two fMRIs, and $10 for travel expenses for each of 3 visits. Your child can also win up to $15 
for playing the game in the fMRI scanner. Payments are provided in the form of checks. Checks 
require some time to be prepared and will be given as available.
Tax law may require the Mount Sinai Finance Department to report the amount of payment received 
from Mount Sinai to the Internal Revenue Service (IRS) or other agencies, as applicable.  Generally, 
this reporting would take place if payments received equal $600 or more from Mount Sinai in a 
calendar year.  You would be responsible for the payment of any tax that may be due.
POSSIBLE BENEFITS:
It is important to know that your child may not get any benefit from taking part in this research.  Others 
may not benefit either.  However, possible benefits may be improvement in ADHD symptoms. After 
study participation has ended, the study team will also be able to refer you to continuing care 
elsewhere. 
 
REASONABLY FORESEEABLE RISKS AND DISCOMFORTS:
Although Adderall is FDA approved for treatment of ADHD in children and is generally considered to 
be safe, some common side effects of Adderall include: insomnia, loss of appetite, irritability, 
headache, occasional moodiness, or increased tics. Other more serious adverse effects such as 
palpitations and increased heart rate have been documented.
Effective Date: 11/8/2022
End Date:11/7/2023


THE MOUNT SINAI HEALTH SYSTEM 
PERMISSION FORM FOR A CHILD TO PARTICIPATE IN A RESEARCH STUDY
AND AUTHORIZATION FOR USE AND DISCLOSURE OF MEDICAL INFORMATION
Icahn School of Medicine at Mount Sinai
Page 7 of 15
Study ID #: GCO 17-1321
           Form Version Date: 4/1/2022
*Throughout this document “child” refers to a minor under applicable state law and “you” refers to any individual 
who may legally act on the minor’s behalf (e.g. parent or legal guardian)
---------------------------------------------------------FOR IRB USE ONLY--------------------------------------------------------------
Rev 6.22.16
There are no known risks associated with MRI, although some children do not like to be in enclosed 
spaces, and some children do not like the noise associated with the machines. We provide time in the 
mock scanners to let the children become accustomed to the scanners, and this helps to reduce any 
psychological discomfort associated with the scanning.
There is always risk of loss of private information, but there are procedures in place to minimize the 
risk.  Your information is held in locked cabinets, and the Mount Sinai computer system uses firewalls, 
passwords and encryption systems to protect your privacy. This risk is expected to occur rarely 
In addition to these risks are there are general risks:

Psychological risks your child may feel discomfort while talking to the clinician about 
adverse life events and traumatic experiences. The assessments are being conducted by 
licensed, trained mental health professionals who use best standards of care and 
assessment when working with your child, so this risk is considered minimal.

Legal risks (for example, in case of newly uncovered information about child abuse the 
team may need to report to the child protective services). These occasions are expected to 
occur rarely.

Risk of loss of private information; this risk always exists, but there are procedures in place 
to minimize the risk.  
OTHER POSSIBLE OPTIONS TO CONSIDER:
You may decide not to permit your child to take part in this research study without any penalty.  The 
choice is totally up to you.
Instead of being in this research study, the choices may include trying Adderall or another FDA 
approved medication with a clinical team, such as your pediatrician, or through your child’s clinic.
The important risks and possible benefits of these alternatives are listed below: 

All medications have potential of side effects

There is always potential of loss of information, psychological discomfort, or other risks of 
being evaluated, whether in a clinical setting or in a research setting. 

Your clinical treatment team can provide you with more treatment options, such as other FDA 
approved medications (e.g., Ritalin, Strattera, Intuniv, etc), or other preparations of medication 
that do not need to be taken in pill form (e.g., patches).
Effective Date: 11/8/2022
End Date:11/7/2023


THE MOUNT SINAI HEALTH SYSTEM 
PERMISSION FORM FOR A CHILD TO PARTICIPATE IN A RESEARCH STUDY
AND AUTHORIZATION FOR USE AND DISCLOSURE OF MEDICAL INFORMATION
Icahn School of Medicine at Mount Sinai
Page 8 of 15
Study ID #: GCO 17-1321
           Form Version Date: 4/1/2022
*Throughout this document “child” refers to a minor under applicable state law and “you” refers to any individual 
who may legally act on the minor’s behalf (e.g. parent or legal guardian)
---------------------------------------------------------FOR IRB USE ONLY--------------------------------------------------------------
Rev 6.22.16

Your clinical treatment team may also provide treatment for a longer period of time, as this 
study is a short-term trial. 
IN CASE OF INJURY DURING THIS RESEARCH STUDY:
If your child is injured or made sick from taking part in this research study, medical care will be 
provided. Generally, this medical care will be billed to you and/or your child’s health care insurance in 
the ordinary manner and you will be responsible for all treatment costs not covered by your child’s 
insurance, including deductibles, co-payments and coinsurance. This does not prevent you from 
seeking payment for injury related to malpractice or negligence. Contact the investigator for more 
information.
ENDING PARTICIPATION IN THE RESEARCH STUDY:
You may decide to stop your child’s participation in this research study at any time without any 
penalty. This will not affect your or your child’s ability to receive medical care at any of the Mount Sinai 
Health System hospitals or to receive any benefits to which you, or your child, are otherwise entitled.
If you decide to stop your child’s participation in the research study, please contact the Principal 
Investigator or the research staff. At that point, we will ask you to complete some safety assessments 
in order to make certain that your child is not experiencing any side effects. 
If you decide to stop your child’s participation in the research study, already collected information may 
not be removed from the research study database and will continue to be used to complete the 
research analysis. You may be asked whether the investigator can collect information from your 
child’s routine medical care. If you agree, this data will be handled the same as research data.  
You may also withdraw your permission for the use and disclosure of any of your child’s protected 
information for research, but you must do so in writing to the Principal Investigator at the address on 
the first page. Even if you withdraw your authorization, the Principal Investigator for the research 
study may still use the information that was already collected if that information is necessary to 
complete the research study.  Your child’s health information may still be used or shared after you 
withdraw your authorization if your child has an adverse event (a bad effect) from participating in the 
research study.
Withdrawal without your permission: The study doctor, the sponsor or the institution may stop your 
child’s involvement in this research study at any time without your permission. This may be because 
the research study is being stopped, the instructions of the study team have not been followed, the 
investigator believes it is in your child’s best interest, or for any other reason. If specimens or data 
have been stored as part of the research study, they too can be destroyed without your permission.  
Effective Date: 11/8/2022
End Date:11/7/2023


THE MOUNT SINAI HEALTH SYSTEM 
PERMISSION FORM FOR A CHILD TO PARTICIPATE IN A RESEARCH STUDY
AND AUTHORIZATION FOR USE AND DISCLOSURE OF MEDICAL INFORMATION
Icahn School of Medicine at Mount Sinai
Page 9 of 15
Study ID #: GCO 17-1321
           Form Version Date: 4/1/2022
*Throughout this document “child” refers to a minor under applicable state law and “you” refers to any individual 
who may legally act on the minor’s behalf (e.g. parent or legal guardian)
---------------------------------------------------------FOR IRB USE ONLY--------------------------------------------------------------
Rev 6.22.16
CONTACT PERSON(S):
If you have any questions, concerns, or complaints at any time about this research, or you think the 
research has hurt your child, please contact the office of the research team and/or the Principal 
Investigator at phone number 212-659-8775
If your child experiences an emergency during participation in this research, contact 911 or go to the 
emergency room. You may also call, in an emergency, 917-748-8695
This research has been reviewed and approved by an Institutional Review Board. You may reach a 
representative of the Program for the Protection of Human Subjects at the Icahn School of Medicine 
at Mount Sinai at telephone number (212) 824-8200 during standard work hours for any of the 
reasons listed below. This office will direct your call to the right person within the Mount Sinai Health 
System:

Your questions, concerns, or complaints are not being answered by the research team.

You cannot reach the research team.

You are not comfortable talking to the research team.

You have questions about rights of research subjects.

You want to get information or provide input about this research.
DISCLOSURE OF FINANCIAL INTERESTS:
Sometimes, physicians/researchers receive payments for consulting or similar work performed for 
industry.  Effective September 2014 Mount Sinai reviews only payments to an individual totaling more 
than $5,000 a year per entity when determining potential conflicts of interest.  If you have questions 
regarding industry relationships, we encourage you to talk your physician/researcher or visit our 
website at http://icahn.mssm.edu/ where Mount Sinai publicly discloses the industry relationships of 
our faculty. 
In the past, Dr. Jeffrey Newcorn (the Principal Investigator in this study) received financial 
compensation as an advisory board member for Shire Pharmaceuticals (manufacturer of Adderall, the 
drug whose effects on the brain are being evaluated in this study). 
Currently, Dr. Newcorn receives financial compensation as a consultant or advisory board member 
from other companies that either develop or assess treatments for ADHD. 
Effective Date: 11/8/2022
End Date:11/7/2023


THE MOUNT SINAI HEALTH SYSTEM 
PERMISSION FORM FOR A CHILD TO PARTICIPATE IN A RESEARCH STUDY
AND AUTHORIZATION FOR USE AND DISCLOSURE OF MEDICAL INFORMATION
Icahn School of Medicine at Mount Sinai
Page 10 of 15
Study ID #: GCO 17-1321
           Form Version Date: 4/1/2022
*Throughout this document “child” refers to a minor under applicable state law and “you” refers to any individual 
who may legally act on the minor’s behalf (e.g. parent or legal guardian)
---------------------------------------------------------FOR IRB USE ONLY--------------------------------------------------------------
Rev 6.22.16
If you have questions regarding paid relationships that your physician/researcher may have with 
industry, we encourage you to talk with him or her, or check for industry relationships posted on 
individual faculty pages on our website at http://icahn.mssm.edu/.
As you take part in this research project it will be necessary for the research team and others to use 
and share some of your child’s private protected health information. Consistent with the federal Health 
Insurance Portability and Accountability Act (HIPAA), we are asking your permission to receive, use 
and share that information.
What protected health information is collected and used in this study, and might also be disclosed 
(shared) with others?
As part of this research project, the research team at the hospital(s) involved in the research will 
collect your child’s: name, address, telephone/fax numbers, dates of birth, admission, discharge, 
social security number, medical records number, other unique codes.
The researchers will also get information from your child’s medical record including your electronic 
medical record, your hospital or clinic, and/or your private doctor.
During the study the researchers will gather information by: 

taking a medical history (includes current and past medications or therapies, illnesses, 
conditions or symptoms, family medical history, allergies, etc.)

doing a physical examination that generally also includes blood pressure reading, heart rate, 
breathing rate and temperature

completing the tests, procedures, questionnaires and interviews explained in the description 
section of this consent

reviewing HIV-related information, which includes any information indicating that your child has 
had an HIV related test, or have HIV infection, HIV related illness or AIDS, or any information 
which could indicate that your child has been potentially exposed to HIV 

reviewing mental health records 

reviewing alcohol and/or substance abuse records

reviewing psychotherapy notes 
Why is your child’s protected health information being used?
Effective Date: 11/8/2022
End Date:11/7/2023


THE MOUNT SINAI HEALTH SYSTEM 
PERMISSION FORM FOR A CHILD TO PARTICIPATE IN A RESEARCH STUDY
AND AUTHORIZATION FOR USE AND DISCLOSURE OF MEDICAL INFORMATION
Icahn School of Medicine at Mount Sinai
Page 11 of 15
Study ID #: GCO 17-1321
           Form Version Date: 4/1/2022
*Throughout this document “child” refers to a minor under applicable state law and “you” refers to any individual 
who may legally act on the minor’s behalf (e.g. parent or legal guardian)
---------------------------------------------------------FOR IRB USE ONLY--------------------------------------------------------------
Rev 6.22.16
Your personal contact information, and that of your child, is important to be able to contact you during 
the study. Your child’s health information and the results of any tests and procedures being collected 
as part of this research study will be used for the purpose of this study as explained earlier in this 
consent form. The results of this study could be published or presented at scientific meetings, 
lectures, or other events, but would not include any information that would let others know who your 
child is, unless you give separate permission to do so.
The Principal Investigator may also use and share the results of these tests and procedures to treat 
your child in collaboration with others in the Mount Sinai Health System.
The research team and other authorized members of The Mount Sinai Health System (“Mount Sinai”) 
workforce may use and share your child’s information to ensure that the research meets legal, 
institutional or accreditation requirements. For example, the School’s Program for the Protection of 
Human Subjects is responsible for overseeing research on human subjects, and may need to see 
your child’s information. If any payments for taking part in this study, the Mount Sinai Finance 
Department may need names, addresses, social security numbers, payment amounts, and related 
information for tax reporting purposes.  If the research team uncovers abuse, neglect, or reportable 
diseases, this information may be disclosed to appropriate authorities. 
Who, outside Mount Sinai, might receive your child’s protected health information?
As part of the study, the Principal Investigator, study team and others in the Mount Sinai workforce 
may disclose your child’s protected health information, including the results of the research study tests 
and procedures, to the following people or organizations: (It is possible that there may be changes to 
the list during this research study; you may request an up-to-date list at any time by contacting the 
Principal Investigator.)
-
Other collaborating research center(s) and their associated research/clinical staff who are 
working with the investigators on this project: James Blair, PhD at the Child and 
Adolescent Mental Health Centre, Mental Health Services, Capital Region of Denmark, 
Copenhagen, Denmark or the Boys Town National Children’s Hospital. 
-
The sponsoring government agency and/or their representative who need to confirm the 
accuracy of the results submitted to the government or the use of government funds: 
National Institute of Health
-
A Data Safety Monitoring Board or other committee that will monitor the study on an 
ongoing basis for safety.
-
The United States Food and Drug Administration (FDA)
Effective Date: 11/8/2022
End Date:11/7/2023


THE MOUNT SINAI HEALTH SYSTEM 
PERMISSION FORM FOR A CHILD TO PARTICIPATE IN A RESEARCH STUDY
AND AUTHORIZATION FOR USE AND DISCLOSURE OF MEDICAL INFORMATION
Icahn School of Medicine at Mount Sinai
Page 12 of 15
Study ID #: GCO 17-1321
           Form Version Date: 4/1/2022
*Throughout this document “child” refers to a minor under applicable state law and “you” refers to any individual 
who may legally act on the minor’s behalf (e.g. parent or legal guardian)
---------------------------------------------------------FOR IRB USE ONLY--------------------------------------------------------------
Rev 6.22.16
-
The United States Department of Health and Human Services and the Office of Human 
Research Protection.
In almost all disclosures outside of Mount Sinai, you will not be identified by name, social security 
number, address, telephone number, or any other direct personal identifier. Some records and 
information disclosed may be identified with a unique code number. The Principal Investigator will 
ensure that the key to the code will be kept in a locked file, or will be securely stored electronically. 
The code will not be used to link the information back to you without your permission, unless the 
Institutional Review Board allows it after determining that there would be minimal risk to your privacy. 
The Certificate of Confidentiality obtained from the Department of Health and Human Services will not 
be used to prevent disclosure to local authorities of child abuse and neglect, or harm to self or others. 
It is possible that a sponsor or their representatives, a data coordinating office, or a contract research 
organization, will come to inspect your records. Even if those records are identifiable when inspected, 
the information leaving the institution will be stripped of direct identifiers.  Additionally, the Office for 
Human Research Protections (OHRP) of the Department of Health and Human Services as well as 
the Food and Drug Administration (FDA) will be granted direct access to your child’s medical records 
for verification of the research procedures and data. They are authorized to remove information with 
identifiers if necessary to complete their task. By signing this document, you are authorizing this 
access. We may publish the results of this research. However, we will keep your name and other 
identifying information confidential.
For how long will Mount Sinai be able to use or disclose your child’s protected health information? 
Your authorization for use of your child’s protected health information for this specific study does not 
expire.
Will you be able to access your child’s records?
During participation in this study, you will have access to your child’s medical record and any study 
information that is part of that record. The investigator is not required to release research information 
that is not part of your child’s medical record to you.
Do you need to give us permission to obtain, use or share to you or your child health information?
NO! If you decide not to let us obtain, use or share your child’s health information you should not sign 
this form, and your child will not be allowed to volunteer in the research study. If you do not sign, it will 
not affect treatment, payment or enrollment in any health plans or affect eligibility for benefits.
Can you change your mind?
You may withdraw your permission for the use and disclosure of any of your child’s protected 
information for research, but you must do so in writing to the Principal Investigator at the address on 
the first page. Even if you withdraw your permission, the Principal Investigator for the research study 
Effective Date: 11/8/2022
End Date:11/7/2023


THE MOUNT SINAI HEALTH SYSTEM 
PERMISSION FORM FOR A CHILD TO PARTICIPATE IN A RESEARCH STUDY
AND AUTHORIZATION FOR USE AND DISCLOSURE OF MEDICAL INFORMATION
Icahn School of Medicine at Mount Sinai
Page 13 of 15
Study ID #: GCO 17-1321
           Form Version Date: 4/1/2022
*Throughout this document “child” refers to a minor under applicable state law and “you” refers to any individual 
who may legally act on the minor’s behalf (e.g. parent or legal guardian)
---------------------------------------------------------FOR IRB USE ONLY--------------------------------------------------------------
Rev 6.22.16
may still use your child’s protected information that was already collected if that information is 
necessary to complete the study.  Your child’s health information may still be used or shared after you 
withdraw your authorization should your child have an adverse event (a bad effect) from being in the 
study. If you withdraw your permission to use your child’s protected health information for research 
that means your child will also be withdrawn from the research study, but standard medical care and 
any other benefits to which your child is entitled will not be affected. You can also tell us you want to 
withdraw your child from the research study at any time without canceling the Authorization to use 
your child’s data.
If you have not already received it, you will also be given The Hospital’s Notice of Privacy Practices 
that contains more information about how The Hospital uses and discloses protected health 
information.
It is important for you to understand that once information is disclosed to others outside Mount Sinai, 
the information may be re-disclosed and will no longer be covered by the federal privacy protection 
regulations. However, even if information will no longer be protected by federal regulations, where 
possible, Mount Sinai has entered into agreements with those who will receive the information to 
continue to protect confidentiality.
If as part of this research project your child’s medical records are being reviewed, or your child’s 
medical history is being taken, it is possible that HIV-related information may be revealed to the 
researchers.  If that is the case, the following information concerns you.  If this research does not 
involve any review of medical records or questions about your child’s medical history or conditions, 
then the following section may be ignored.  
_________________________________________________________________________________
Notice Concerning HIV-Related Information
If you are authorizing the release of HIV-related information, you should be aware that the recipient(s) is 
(are) prohibited from re-disclosing any HIV-related information without your authorization unless permitted 
to do so under federal or state law.  You also have a right to request a list of people who may receive or 
use your child’s HIV-related information without authorization.  If you or your child experience 
discrimination because of the release or disclosure of HIV-related information, you may contact the New 
York State Division of Human Rights at (888) 392-3644 or the New York City Commission on Human 
Rights at (212) 306-5070.  These agencies are responsible for protecting your rights.
_____________________________________________________________________________________
Certificate of Confidentiality: To further protect your child’s privacy, the researchers have obtained a 
Certificate of Confidentiality from the Department of Health and Human Services. This Certificate does 
not mean that the Department of Health and Human Services approves of this research. Rather, it is 
Effective Date: 11/8/2022
End Date:11/7/2023


THE MOUNT SINAI HEALTH SYSTEM 
PERMISSION FORM FOR A CHILD TO PARTICIPATE IN A RESEARCH STUDY
AND AUTHORIZATION FOR USE AND DISCLOSURE OF MEDICAL INFORMATION
Icahn School of Medicine at Mount Sinai
Page 14 of 15
Study ID #: GCO 17-1321
           Form Version Date: 4/1/2022
*Throughout this document “child” refers to a minor under applicable state law and “you” refers to any individual 
who may legally act on the minor’s behalf (e.g. parent or legal guardian)
---------------------------------------------------------FOR IRB USE ONLY--------------------------------------------------------------
Rev 6.22.16
intended to ensure that your child’s identity as a participant in this research study will not have to be 
disclosed as a result from a subpoena, for the purpose of identifying you in any federal, state, or local 
civil, criminal, administrative, legislative, or other proceedings other than to the FDA or OHRP as 
identified above. The research staff will not share any of your child’s research information with anyone 
who is not a member of the research team, including any family members or friends, other than to 
those identified above. However, you should know that if we learn that your child or someone else is 
threatened with serious harm, such as a child or an elderly person being abused, the investigators 
may notify the appropriate authorities if necessary to protect your child or others.  A Certificate of 
Confidentiality does not prevent you, your child, or a member of your family from voluntarily releasing 
information about your child or his/her involvement in this research. This means that you. Your child 
and your family must also actively protect your child’s privacy. If an insurer or employer learns about 
your child’s research participation, and you agree that they can have your child’s research 
information, then the researchers may not use the Certificate of Confidentiality to keep this information 
from them. 
Effective Date: 11/8/2022
End Date:11/7/2023


THE MOUNT SINAI HEALTH SYSTEM 
PERMISSION FORM FOR A CHILD TO PARTICIPATE IN A RESEARCH STUDY
AND AUTHORIZATION FOR USE AND DISCLOSURE OF MEDICAL INFORMATION
Icahn School of Medicine at Mount Sinai
Page 15 of 15
Study ID #: GCO 17-1321
           Form Version Date: 4/1/2022
---------------------------------------------------------FOR IRB USE ONLY--------------------------------------------------------------
Rev 6.22.16
Signature Block for Research Involving Children
Your signature documents your permission for the child named below to take part in this research and to the 
use and disclosure of this child’s protected health information. A signed and dated copy will be given to you.
Printed name of child
Date
Signature of parent or guardian
Time 
Printed name of parent or guardian

Parent

Guardian (May provide permission 
only if legally authorized to consent to 
the child’s general medical care.)
Signature of second parent
Date 
Printed name of second parent
Time
Note on Second Parent:  If the IRB determined both parents must give permission unless an exception below applies, 
and if documented permission of the second parent of this child is not obtained, indicate the reason: (select one)

Second parent is deceased

Second parent is unknown 

Second parent is incompetent

Second parent is not reasonably available

Only one parent has legal responsibility for the care and custody of the child
Person Explaining Study and Obtaining Consent 
Signature of person obtaining consent 
Date 
Printed name of person obtaining consent
Time
If a witness is required to observe the consent process , document below: 
My signature below documents that the information in the consent document and any other written information was 
accurately explained to, and apparently understood by, the parent(s)/guardian, and that permission was freely given.
Signature of witness to consent process
Date 
Printed name of person witnessing consent process
Time
Assent

Obtained

Not obtained because the capability of the child is so limited that the child cannot reasonably be consulted.
Effective Date: 11/8/2022
End Date:11/7/2023